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I. INTRODUCTION

A. Overview
Dopamine, a major neurotransmitter in the mammalian central nervous
system, is involved in the control of locomotor activity, and also in pathways
regulating behavior and reward (Schultz, 2002).

The dopamine transporter

(DAT) plays a critical role in the synaptic clearance of dopamine by mediating the
reuptake of dopamine from the extracellular space. Following the invasion of the
nerve terminal by an action potential (in dopaminergic neurons), dopamine is
released into the synaptic cleft by Ca2+-mediated exocytosis.

The released

dopamine binds to receptors on the postsynaptic membrane and activates
dopaminergic signal transduction pathways. The neurotransmission of dopamine
is terminated primarily by reuptake of dopamine into the presynaptic cell via the
dopamine transporter (Fig. 1).

Thus, DAT is, in part, responsible for the

maintenance of dopaminergic homeostasis in neuronal cells.

The dopamine

transporter belongs to a large class of transporters referred to as Na+/Cl-dependent transporter or neurotransmitter: sodium symporter (NSS) family.
Members of this class include: the serotonin transporter (SERT), norepinephrine
transporter (NET), epinephrine transporter (ET), and also transporters for
betaine, creatine, GABA, glycine, proline, and taurine (Amara and Arriza, 1993;
Amara and Kuhar, 1993). For these transporters, the reuptake process involves
the translocation of substrate and cosubstrates Na+ and Cl- across the plasma
membrane. This transport process also involves a conformational change in the

2
transporter protein (Rudnick and Clark, 1993). In the case of DAT, the outwardfacing transporter binds one Cl- and two Na+ ions and one dopamine molecule.
These binding events permit the transporter to undergo a conformational change
to an inward-facing conformation. This internal-facing form dissociates Na+, Cl-,
and dopamine to the cytoplasm.

On binding internal K+, the transporter

undergoes another conformational change (to an outward-facing conformation)
which allows the carrier to dissociate K+ on the cell exterior. Consequently, the
original form of the transporter is generated which can then initiate another round
of transport by binding external Na+, Cl-, and dopamine.
DAT is expressed almost exclusively in dopaminergic neurons of the
substantia nigra and the ventral tegmental area of the brain (Ciliax et al., 1995;
Freed et al., 1995). The areas of the brain where dopaminergic neurons are
found to project include the striatum, nucleus accumbens and the prefrontal
cortex. DAT is also expressed throughout the cell on axons, dendrites and the
soma (Nirenberg et al., 1997).
DAT

is

the

primary

target

of

psychostimulant

drugs

including

methylphenidate, cocaine, and amphetamines; such drugs bind to DAT and
inhibit the reuptake of dopamine (Kuhar et al., 1991). Thus, a convincing clinical
rationale exists for understanding the structure and function of this transporter
protein. In addition to inhibiting uptake of extracellular dopamine, amphetamines
also stimulate efflux of intracellular dopamine (Jones et al., 1998). The resultant
effect of psychostimulant drug action on DAT is increased accumulation of
dopamine in the synaptic cleft causing potentiated neurotransmission of
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dopamine in those areas of the brain associated with reward and reinforcement.
Consequently, the motor and reward pathways of the midbrain are activated,
triggering the increased locomotor activity and euphoria associated with
psychostimulant drug use.

AMPH
MPP+

Cocaine
GBR12,909
BZT

Tyrosine
L-DOPA
DA
DA

DAT

DA receptors

Figure 1. Schematic representation of dopamine synaptic terminal.
DAT is localized to presynaptic sites where it is vital for the termination of dopaminergic
neurotransmission and maintenance of presynatic dopamine storage. DA, dopamine; AMPH,
amphetamine; DAT, Dopamine transporter; BZT, benztropine.

Experiments

using

mice

lacking

the

dopamine

transporter

have

demonstrated the importance of the transporter in psychostimulant action (Giros
et al., 1996). High doses of cocaine did not increase locomotor activity above the
already elevated levels in these DAT knock-out mice. Nonetheless, it is pertinent
to note that not all the behavioral effects of cocaine can be ascribed solely to
DAT. Subsequent studies evaluating both cocaine self-administration (Rocha et
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al., 1998) and conditioned place preference (Sora et al., 1998) in DAT knock-out
mice showed that cocaine self-administration and conditioned place preference
were intact.

Mice with a double disruption of both dopamine and serotonin

transporter genes exhibited no conditioned place preference in response to
cocaine.

The serotonin transporter may contribute to cocaine reward and

reinforcement naturally (Sora et al., 2001) or in compensation for the absence of
DAT.

B. Statement of the problem
Cocaine abuse is growing at an alarming rate in the U.S. It is estimated that
more than 23 million people in the U.S. have tried cocaine, nearly 40,000 people
use it daily, and 5,000 new users are added each day (SAMHSA, 1997). Drug
abuse generally inflicts severe medical, social, and judicial costs upon the
society. The central problem with cocaine addiction is that even after treatment
and extended periods of abstinence the risk of relapse is high. The primary
feature of cocaine addiction is the compulsive seeking of the drug that results in
failure to resist taking the drug. The abuse liabilities of cocaine result from its
euphorigenic and reinforcing properties.

Neurochemical studies on effects of

cocaine show that the mesolimbic and mesocortical dopamine systems of the
brain are involved in psycholocomotor stimulant reward function. The behavioral
profile that is associated with cocaine addiction results from the accumulation of
dopamine in the synapse and its actions at one or more of the D1- D5 dopamine
receptors. Thus, the reinforcing property of cocaine is caused by potentiated
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neurotransmission of dopamine in mesolimbic pathways. Cocaine binds to the
dopamine transporter and inhibits dopamine reuptake leading to a distortion in
dopamine homeostasis. No definitive information exists on the conformation of
neurotransmitter transporter proteins, as no crystallographic or high resolution
data are available. At present the binding sites for dopamine or cocaine on DAT
have not been well elucidated. Using site-directed mutagenesis and chimeric
studies, investigators have identified certain amino acid residues in the primary
structure of the dopamine transporter that are important for substrate and/or
inhibitor binding to DAT. Of the several DAT mutants published so far, aspartate79 (D79) of the rat DAT is still the only residue whose mutation caused an
increase in both Km for dopamine uptake and Ki for dopamine to compete for the
cocaine analog [3H]WIN35,428 binding site (Kitayama et al., 1992).

This

suggested a critical role for D79 in DAT function. In a separate study, Barker and
coworkers (1999) showed that in both human norepinephrine and rat serotonin
transporters, the replacement of the aligned aspartates with uncharged amino
acids resulted in the disruption of substrate transport.

For the reason that

dopamine and cocaine possess a protonated nitrogen atom at physiological pH,
it was postulated that the positively charged amino group of dopamine or
protonated nitrogen of cocaine directly interacts with the negatively charged
carboxylate of D79 and that ionic competition between cocaine and dopamine is
the mechanism of cocaine inhibition of dopamine uptake (Carroll et al., 1992).
Several lines of evidence, however, directly contradict this hypothesis. In their
studies with neutral 8-oxa analogs of WIN35, 428 and cocaine, Madras et al.
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(1996) and Kozikowski et al. (1999) have proven that both compounds are quite
potent inhibitors of dopamine transport by DAT relative to the charged, nitrogenbased parent compounds. Nevertheless, the D79 residue appears to be crucial
to DAT function. The D79 residue is one of two charged residues that reside in
the hydrophobic lipid bilayer. Furthermore, amino acid sequence alignment of
transmembrane domain 1 from various members of the NSS transporter gene
family, which the DAT belongs to, shows that an aspartic acid at this position is
conserved only in those members whose substrates have an aromatic moiety. It
is likely that the role of the D79 side chain may be to contribute to an aromatic
binding pocket for DAT ligands. Therefore, the primary focus of this study was to
determine whether D79 was involved in the recognition of some feature of the
DAT substrate or inhibitor structure. The specific hypothesis to be tested here is
that the D79 residue is pivotal to DAT function and that the side chain of this
residue may form intramolecular contacts that supported an aromatic binding
pocket.
In the course of this study using mammalian cell lines stably-transfected
with WT DAT cDNAs, it was observed that the dopamine uptake inhibition
potency (DUIP) of a given inhibitor will fluctuate even though the apparent
binding affinity of the drug remained static. The nature of this phenomenon was
investigated by examining three possible influences on DAT function at the level
of the cultured cell: the age of the cell line (measured by cell passage number),
the density of the cell monolayer (i.e., percent confluence), and the effect of
varying DAT expression level by manipulation of transfection conditions. The
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specific hypothesis to be tested in this case is that the DUIP of DAT inhibitors in
CHO cells stably transfected with WT DAT fluctuate as a function of cell state.

C. Literature Survey
1. Structure of the Dopamine Transporter
The human DAT contains 620 amino acids in its primary sequence. As
mentioned earlier, the three-dimensional structure of DAT, or any other member
of the family of mammalian neurotransmitter transporters, is unknown due to the
absence of X-ray crystallographic or high-resolution structural information.
Nevertheless, the topological assignment of the dopamine transporter has been
made possible by the use of analytical techniques such as substituted cysteine
accessibility method (SCAM), site-directed mutagenesis, and hydrophobicity
studies.

Hydrophobicity analysis of the primary sequences of mammalian

monoamine transporters indicates that monoamine transporters are polytopic
membrane proteins containing 12 transmembrane domains connected by
alternating extracellular and intracellular loops with the N- and C-termini located
in the cytosol (Fig. 2).

The cytoplasmic location of N-terminal and the

extracellular location of the sequence between transmembrane (TM) domain 3
and 4 of DAT has been demonstrated (Nirenberg et al., 1996). In addition, the
topological assignments of four cysteine residues have been verified using
SCAM analysis (Ferrer and Javitch, 1998).

C90 and C306 are located

extracellularly, and C135 and C342 appear to be intracellular (Ferrer and Javitch,
1998). Furthermore, three residues (two histidines and on glutamate) predicted
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to be on the extracellular face of the human dopamine transporter, H193 (located
in extracellular loop 2), H375 (located in TM 7), and E396 (TM 8), have been
shown to constitute three coordinates of an endogenous Zn2+-binding site. The
participation of these residues in binding the small Zn2+ ion implies a nearness of
extracellular loop 2, TM 7, and TM 8 in the tertiary structure of the human DAT
(Norregaard et al., 1998; Loland et al., 1999). DAT is a heavily glycosylated
protein with an apparent molecular mass of ~80 kDa as determined by gel
electrophoresis. The N-deglycosylation of mature DAT reduced the molecular
mass to ~50 kDa (Patel, 1997). The bulk of cloned dopamine transporters have
at least three consensus sites for N-linked glycosylation in the second
extracellular loop located between TMs 3 and 4. Mutational studies have shown
that this glycosylation is very important for the activity and stability of the
transporters at the surface, but does not seem to be important for the regulation
of the intrinsic transport activity (Torres et al., 2003). The stability and targeting
of the human norepinephrine transporter to the cell surface largely depend on
glycosylation of the transporter at the consensus sites (Melikian et al., 1996).
This effect may also be applicable to the dopamine transporter protein.
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Extracellular

Intracellular

C

N

Figure 2. Schematic illustration of plasmalemmal monoamine transporters topology.

Two cysteines (C180 and C189) in the second extracellular loop are
predicted to form a disulfide bridge important to DAT cell surface expression
(Wang et al., 1995). Substitutions of these cysteines severely decreased the
expression of the mutant transporters. Immunocytochemistry data showed that
COS cells transfected with C180A and C189A mutant DAT displayed reduced
membrane staining and prominent staining in perinuclear regions consistent with
Golgi apparatus (Wang et al., 1995). These results suggest that cysteines in the
DAT second extracellular loop may provide sulfide residues crucial to full
transporter expression.
DAT

is

phosphorylated

in

stably

expressing

cells

and

striatal

synaptosomes (Vaughan et al., 1997). Protein kinase C-mediated DAT
phosphorylation (Vaughan et al., 1997) causes internalization of the transporter
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protein (Pristupa et al., 1998; Melikian and Buckley, 1999) and down-regulation
of transporter activity (Kitayama et al., 1994; Vaughan et al., 1997; Zhang et al.,
1997).

There are several DAT consensus sites for protein kinase

phosphorylation (Giros et al., 1992); nonetheless, DAT function does not appear
to be regulated by phosphorylation at these sites. Deletion of all possible protein
kinase C sites did not affect the ability of protein kinase C activators or inhibitors
to regulate dopamine transport (Granas et al., 2003). It is possible, therefore,
that direct dopamine transporter phosphorylation might occur at nonconsensus
phosphorylation sites. It is also likely that DAT phosphorylation is considerably
influenced by ligand occupancy.

2. Substrate and Inhibitor Selectivity of the DAT
DAT cloning and characterization has been achieved for several species
(Giros et al., 1991, 1992; Miller et al., 2001; Jayanthi et al., 1998; Kilty et al.,
1991; Usdin et al., 1991; Porzgen et al., 2001; Gallant et al., 2003; Shimada et
al., 1991). The DAT has a well-defined and distinctive pharmacological profile.
Dopamine uptake by DAT is inhibited by a variety of compounds including the
psychostimulants cocaine, mazindol, and methylphenidate, and a few selective
compounds that include the GBR compounds 12909 and 12935 and the
muscarinic antagonist benztropine. In addition to clearing dopamine, DAT can
transport

amphetamines

and

the

dopaminergic

neurotoxin

1-methyl-4-

phenylpyridinium ion (MPP+), which triggers a Parkinson’s disease-like
syndrome. A brief description of selected DAT inhibitors is given below.
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Benztropines
Benztropine (3α-diphenylmethoxytropane, cogentin1) is a tropane-based
dopamine uptake inhibitor. It is an anticholinergic agent which is used for the
treatment of symptoms associated with Parkinson’s disease.

Benztropine is

different from cocaine by possessing a diphenylmethoxy group attached to the C3 position of the tropane ring. Para-substitution of a halogen-group on one of the
phenyl rings of benztropine augments its potency for inhibition of dopamine
uptake.

It has been shown that optimal binding affinity at the DAT was

accomplished when small halogens such as fluorine and chlorine were placed in
the para- and/or meta- positions of one or both phenyl rings. This modification
caused a diminution in potency for inhibition of serotonin and norepinepherine
uptake, resulting in a considerably more dopamine-selective compound than the
parent benztropine.

The following structure–activity relationships for the

benztropines have been established: the diphenyl ether must be in the αstereochemistry and both aryl rings are required and must be free to rotate.
Assessment of benztropine analogs in animal models of cocaine abuse
demonstrated that regardless of binding to DAT with high affinity and exhibiting
potent inhibition of dopamine uptake, in vitro, these compounds did not
demonstrate a cocaine-like behavioral profile (for a review of the structure-activity
studies of benztropine analogs, see Newman and Kulkarni, 2002).
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Benztropine
GBR Compounds
GBR compounds (aryl 1,4-dialkyl piperazines) were modeled after
benztropine. The key structural dissimilarity between benztropine and GBR
compounds is that the GBR compounds have a piperazine ring in place of the
tropane nucleus present in benztropine. One of the most potent compounds in
this group is GBR 12909. In contrast with cocaine, GBR 12909 is not a central
nervous system stimulant. The mechanism of action of GBR 12909 is identical to
that of cocaine. GBR 12909 binds to DAT and inhibit dopamine uptake. GBR
12909 differs from cocaine in that it produces a relatively moderate and longlasting increase in dopamine, which does not produce the same degree of
euphoria compared to the effect of cocaine.
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Mazindol
Mazindol is a dopamine uptake inhibitor with very low abuse liability.
Currently, mazindol, 5-(4-chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1a]isoindole, is marketed in the United States as an anorexic agent (exogenous
obesity) and as an orphan drug for the treatment of Duchenne muscular
dystrophy. It is an effective inhibitor of uptake and binding at DAT, NET and
SERT sites. It blocks the uptake of dopamine and also inhibits [3H]cocaine and
[3H]WIN 35,428 binding.

WIN-type of compounds
The key structural feature of phenyltropanes (WIN-type of compounds) is
that they lack the 3α-benzoyl ester function group present in cocaine. The phenyl
ring is directly attached to the tropane ring. The phenyltropanes were first made
with the intention of obtaining an effective stimulant or antidepressant with
diminished toxicity. These compounds bind to DAT and block dopamine uptake.
WIN35,428 is the prototype compound in this class. Inhibition of [3H]WIN35,428
binding to the DAT is the common radioligand used to determine ligand binding
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affinity due to sufficient specificity to DAT. [3H]WIN35,428 labels both the highand low-affinity binding sites of DAT, just like cocaine, and is resistant to
metabolic and chemical degradation. It also has a high signal-to-noise ratio.

4-ARA-127
4-ARA-127 is a piperidine-based ligand that has been fast-tracked by
NIDA’s Medication Development Group for use as a substitute medication for
cocaine dependence. This compound displays the characteristics of a partial
agonist at the dopamine transporter. The most important pharmacological point
of distinction between this compound and cocaine is its low activity at the
serotonin transporter (with a slight action at other receptor systems as found
through the NIMH screening program). In primate studies, it was established
that this piperidine-based ligand was more weakly reinforcing than cocaine.
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3. Structure-Function Analysis of the Dopamine Transporter
a. Transmembrane (TM) domains.

TM 1
A TM 1 aspartic acid residue common to the plasma membrane
monoamine transporters but not shared by other neurotransmitter: sodium
symporter (NSS) family members is the side chain most frequently proposed to
directly contact both inhibitors and substrates of the dopamine transporter. Of all
the several DAT mutants published so far, aspartate-79 (D79) of the rDAT is the
only residue whose mutation (to glutamate) was reported to cause an increase in
both Km for dopamine uptake, and an increase in Ki for dopamine in competing
for the cocaine analog [3H]WIN35,428 binding site (Kitayama et al., 1992). In
contrast, recent findings with the same D79E DAT mutant showed no effect on
dopamine affinity when compared with WT values. Three-fold losses in cocaine,
WIN 35,428, mazindol and methylphenidate affinities were observed, with little or
no effect on the dopamine uptake inhibition potency (DUIP) for these drugs
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(Wang et al., 2003).

On the other hand, binding affinities and DUIPs for

benztropine and its analogs were altered substantially by the D79E mutation
(Ukairo et al., 2005).

Barker et al. (1999) showed that for the human

norepinephrine transporter (NET) and rat serotonin transporter (SERT), the
replacement of the analogous aspartate residue with uncharged amino acids
resulted in the disruption of substrate transport. These findings led investigators
to believe that the positively charged amino group of dopamine directly interacts
with the negatively charged carboxylate of D79, an approach based on the G
protein-coupled receptor model of a salt bridge between the positively charged
agonist amino group and negatively charged TM domain carboxylate side chain
(Strader et al., 1988).

Consequently, it has been postulated that ionic

competition between cocaine and dopamine is the mechanism by which cocaine
inhibited dopamine uptake (Carroll et al., 1992). The neutral “8-oxa” analogs of
WIN35,428 and cocaine still inhibit DAT, albeit less potently than the charged,
nitrogen-based parent compounds (Madras et al., 1996 and Kozikowski et al.,
1999). Thus, the idea that D79 of the plasma membrane dopamine transporter is
a counter ion for the positively charged substrate amino group is speculative. A
glycine side chain is found at the analogous position in the other NSS family
members including transporters for GABA, betaine, glycine and proline. The
substrates for these transporters share with the monoamines the positively
charged amino group but lack aromatic groups (Wang et al., 2003).

The

presence of an aspartic acid side chain at this position in only those transporters
recognizing aromatic substrates may indicate that the aspartic acid residue
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serves as a ‘strut’ supporting an aromatic binding site for the ligand (Ukairo et al.,
2005). Recent data were not in agreement with, but did not rule out, formation of
a salt bridge between aspartate and either dopamine, cocaine or amphetamine
(Wang et al., 2003; Ukairo et al., 2005). The aspartate (D75) in the analogous
position in NET was intolerant to mutation, and like the DAT, only glutamate
substitution of D98 yielded a functional SERT (Barker et al., 1999). In an effort to
find DAT TM residues capable of directly interacting with the positively charged
moieties of substrates and inhibitors, conserved acidic and tryptophan hDAT
residues were separately mutated and the mutant transporters characterized,
including the TM 1 residues D68 and W84 (Chen et al., 2001). The mutation of
D68 to asparagine (D68N) resulted in 3 - 4 fold losses in affinity for WIN 35,428
and in cocaine DUIP (Chen et al., 2001). The mutation did not appreciably affect
recognition of the classic DAT inhibitor GBR-12909 or most of the
hydroxypiperidine GBR-like analogs tested; however, one such analog, (+)-R,RD-84, sustained a 17-fold affinity loss.

(+)-R,R-D-84 differs from one of the

analogs unaffected by the mutation only in the position of a hydroxyl group.
Thus, it is possible that DAT interacts with GBR analogs by way of hydrogen
bonding between its D68 residue and the hydroxyl groups of these compounds
(Zhen et al., 2004).
Human (W84L) and rat (W84A) DAT substitutions of this tryptophan
residue increased WIN 35,428 affinity and cocaine DUIP without affecting
dopamine Km values (Chen et al., 2001; Lin et al., 2000). It is envisaged that
W84 may contribute to maintaining an intracellular-facing DAT conformation
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(Chen et al., 2001). The Na+-dependent conformational changes required for
DAT function were impaired in hDAT W84L (Chen et al., 2004). This mutant also
displayed Na+ sensitivity differences between cocaine and the diphenylmethoxybearing compounds benztropine and GBR-12,909.

Taken together with the

aforementioned rDAT D79E results, the hDAT W84L findings suggest that TM 1
residues

may

provide

discrimination

between

diphenylmethoxy-bearing

compounds and classic inhibitors such as cocaine, WIN 35,428 and mazindol.
Moreover, of several endogenous hDAT cysteine residues surveyed for
accessibility

to

the

methanethiosulfonate

alkylating

agent

MTSET,

the

benztropine-induced DAT alkylation pattern deviated from those of cocaine, WIN
35,428, mazindol and dopamine only at C90, a residue immediately extracellular
to TM 1 (Reith et al., 2001). It is unclear whether these TM 1-associated inhibitor
selectivities are solely due to DAT conformational differences or are indicative of
TM 1 contributions to inhibitor binding sites.

TM 2
Mutation of rDAT F98 to alanine (F98A), a residue presumed to be located
at the TM 2 extracellular boundary, decreased WIN 35,428 binding 6-fold. The
mutation had no effect on the dopamine uptake affinity, but dopamine turnover
rate was significantly diminished (Lin et al., 1999). F98 is largely conserved in
the NSS family and possibly less likely to directly contact specific uptake
inhibitors. A mouse/Drosophila DAT chimera study led to identification of mDAT
F105 as the residue primarily responsible for the 10-fold higher DUIP of cocaine
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at the mDAT; this position is occupied by methionine in the dDAT. Of several
mutations tested, only the presence of an aromatic side chain at mDAT position
105 retained wildtype-like DUIPs for cocaine.

Substitutions of F105 with

nonaromatic amino acids alanine, serine, threonine, leucine, isoleucine,
asparagine, and glutamine resulted in mutants with diminished cocaine binding
affinity.

Whether the effect of nonaromatic substitution of mDAT F105 on

cocaine DUIP was direct or indirect was not investigated (Wu and Gu, 2003).
Intriguingly, WIN 35,428 affinity at F105A mutant rDAT decreased by only 2-fold
relative to wildtype rDAT (Lin et al., 1999). In contrast with the observation made
in the studies of DAT TM2, substituted cysteine accessibility method (SCAM)
analysis of rSERT TM 2 did not identify residues that directly affected substrate
binding or were accessible to alkylating agents (Sato et al., 2004). Most recently,
random mutagenesis of mDAT TM 2 residues in the vicinity of F105 generated
the triple mutant L104V/F105C/A109V, which suffered 69- and 47-fold DUIP
losses for cocaine and methylphenidate.

The DUIPs for the substrates

amphetamine and methamphetamine at the triple mutant were not significantly
different from those at the wildtype mDAT (Chen et al., 2005).

TM 3
A region of the dopamine transporter surrounding the 3rd transmembrane
domain is considered to be vital for cocaine recognition. Using human/bovine
DAT chimeras a 54 residue segment encompassing TM 3 was identified as
especially crucial for dopamine uptake and WIN 35,428 binding (Lee et al.,
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1998).

Remarkably, replacement of the bDAT TM 3 residue I152 with its

conservative valine counterpart in the hDAT was found to almost single-handedly
confer the superior substrate transport and WIN 35,428 binding characteristics of
the hDAT (Lee et al., 2000). Two positions away, FI54 in TM 3 also appears to
be a cocaine-selective residue in DAT. Mutation of F154 to alanine (F154A)
lowered cocaine affinity by about 10-fold while retaining normal dopamine uptake
activity (Lin and Uhl, 2002).

The F154A mutation also altered cocaine

stereoselectivity. V152 and F154 should be located on opposite faces of DAT
TM 3, implying that both cannot directly contact the ligand. SCAM analysis of TM
3 of rSERT indicated that I172, the residue analogous to hDAT V152, is on the
helical face accessible to ligands and external agents (Chen et al., 1997).
Moreover, I172 and Y176 of rSERT are in or near the binding sites for serotonin
and cocaine (Chen et al., 1997; Chen and Rudnick, 2000). Assuming that TM 3s
of the DAT and SERT have comparable orientations in the plasma membrane,
V152 would be expected to face the ligand pore and F154 would face the lipid
bilayer. F155 of DAT could still face the ligand pore, a residue conserved among
DATs but replaced by tyrosine in SERTs and NETs. The rDAT F155A mutant
sustained a profound loss in apparent affinity for dopamine, but only a mild
decrease in WIN 35,428 affinity (Lin et al., 1999).

TM 5
Replacement of W267 hDAT with leucine forms a mutant DAT with a 3fold decrease in cocaine DUIP when compared with WT hDAT (Chen et al.,
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2001).

Uptake kinetics suggest that W267 contributes to an outward-

(extracellular-) facing DAT conformation (Chen et al., 2001).

This residue is

presumed to border the cytoplasm. Glycine replacement of rDAT P272 modestly
reduced Vmax for dopamine uptake, but decreased WIN 35,428 binding affinity
10-fold without a reduction in rDAT plasma membrane expression. DUIPs for
cocaine, BTCP (1-[1-(2-benzo[b]thiopheneyl)cyclohexyl]piperidine hydrochloride),
mazindol and trihexyphenidyl decreased by over 100-fold (Kopajtic, 1997). A
subsequent study characterized rDAT P272A mutant in uptake and binding
studies. The alanine mutant decreased the affinities for both dopamine and WIN
35,428 binding relative to wildtype rDAT (Lin et al., 2000). Alanine replacement
of the analogous hNET residue P270 yielded undetectable specific binding of
nisoxetine and 11-, 3- and 3-fold decreases in the norepinephrine uptake
inhibition

potencies

respectively.

(NUIPs)

of

nisoxetine,

desipramine

and

cocaine,

Of 10 hNET proline residues mutated, only P270A decreased

recognition of uptake inhibitors by 3-fold or more (Paczkowski and Bryan-Lluka,
2004). The number of TM proline residues is observed to be inexplicably large in
transport proteins when compared with other integral membrane proteins, yet it is
not clear how such TM proline residues affect transporter protein structure and
function (Williams and Deber, 1991; Brandl and Deber, 1996). In general, it has
been postulated that proline residues disrupt α-helices, whereas alanine residues
promote α-helix formation (Barlow and Thornton, 1988). The extent of the αhelical "kink" induced by proline, however, is reliant on its environment (Li et al.,
1996), and especially on neighboring residues (Ri et al., 1999; Visiers et al.,
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2003). Thus, proline residues may serve a structural role in determining protein
infrastructure by influencing helix-helix packing. Functional roles for TM proline
residues may include providing hinges that facilitate signal transduction,
mediating conformational changes via cis-trans isomerization of the bond linking
the proline to the preceding residue of the polypeptide, and providing a geometry
that allows neighboring amide carbonyl oxygen atoms of the polypeptide to serve
as cation binding sites (Sansom et al., 2000; Eisenman and Dani, 1987; Sansom,
1992). The latter functional role is most likely for the monoamine transporters.
Thus, P272 may provide a direct ligand binding site, a key Na+ binding site that
modulates transport or substrate or inhibitor recognition, or simply a kink
necessary to the ligand or ion binding pocket.

TM 6
Mutation of hDAT W311 to leucine (W311L) decreased WIN 35,428
affinity 10-fold and cocaine DUIP over 3-fold while dopamine inhibition of WIN
35,428 binding decreased by over 100-fold (Chen et al., 2001). This mutation
had no effect on the plasma membrane expression of hDAT.

Conversely,

alanine replacement of the rDAT counterpart (W310A) increased WIN 35,428
affinity 4-fold, and dopamine displacement of the cocaine analog was over 200
times more effective (Lin et al., 2000).

The rDAT W310A mutation caused

decreased plasma membrane expression, increased Km and diminished Vmax
for dopamine uptake. The discrepancy in the data obtained for hDAT and rDAT
could be because the rDAT binding was conducted at 4oC, compared to 37oC in
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the hDAT study (Chen et al., 2001).

Two residues away, the hDAT D313N

mutant did not markedly affect WIN 35,428 or cocaine binding under normal
assay conditions, and dopamine affinity was diminished (Chen et al., 2001).
Although it is unlikely to be part of the substrate or inhibitor binding sites, D313
may nevertheless regulate access to external dopamine in a Na+-dependent
fashion.

This residue and W84 have been shown to be involved in cation

interactions, and controls, in part, the ability of Na+ to drive the DAT between
inward- and outward-facing conformations, in turn influencing dopamine access
and Na+-dependent cocaine affinity (Chen et al., 2002; Chen and Reith, 2003).

TM 7
Simultaneous mutation of the rDAT S356 and S359 residues to glycine or
alanine resulted in reductions in WIN 35,428 binding affinity and decreases in
dopamine uptake. These residues are hypothesized to form hydrogen bonding
interactions with the catechol hydroxyl groups of dopamine (Kitayama et al.,
1992).

This model was borrowed from that of Strader and colleagues, who

demonstrated an association between α-adrenergic receptor TM serine residues
and agonist hydroxyl groups (Strader et al., 1989). The fact that a serine side
chain is found at this same position throughout the NSS family, including
transporters for non-catechol substrates, argues against this model.
Finally, alanine replacement of rDAT F361 decreased WIN 35,428 binding
affinity by an order of magnitude without affecting dopamine uptake kinetics (Lin
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et al., 1999).

Positioned at the midpoint of TM 7, this side chain is largely

conserved in the NSS family.

TM 8
For the rDAT, alanine substitution of W406 (W406A) decreased WIN
35,428 binding affinity by 3-fold; decreased Vmax for dopamine uptake by ~10-fold
and increased dopamine uptake and binding affinities. DAT plasma membrane
expression was altered in this mutant (Lin et al., 2000). This residue is not far
from the extracellular boundary and is largely conserved in the NSS family,
although a phenylalanine side chain is found at the same position in the SERT.

b. Extracellular loops (ECL)
Many mutations of recognized extracellular and intracellular residues have
been generated for the purpose of detecting conformational shifts in, or mapping
tertiary structure of, NSS family members.

A few of these mutations were

demonstrated to affect uptake inhibitor recognition. The hDAT C90A mutant was
prepared

toward

generating

a

DAT

species

lacking

endogenous

methanethiosulfonate-reactive cysteine residues (Ferrer and Javitch, 1998). This
mutation did not alter affinity for WIN 35,428, but selectively diminished the DUIP
of benztropine; DUIPs of cocaine, WIN 35,428 and mazindol were unaffected by
the mutation.

This very highly conserved ECL 1 residue is not expected to

directly contact benztropine, but rather to differentially contribute toward
stabilizing benztropine- versus cocaine-preferring DAT conformations (Reith et
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al., 2000; Ferrer and Javitch, 1998). Gether and colleagues have mutated many
extratransmembranous hDAT residues in elucidating the endogenous Zn2+
binding site of the DAT, and in creating new Zn2+ sites toward mapping TM
domain proximities (Loland et al., 2004; Norgaard-Nielsen et al., 2002; Loland et
al., 1999). In the course of this work, the extracellular hDAT mutants E218Q
(ECL 2), E307Q (ECL 3) and D385N (ECL 4) were found to sustain 4- to 5-fold
losses in WIN 35,428 affinity (Loland et al., 1999). Treatment of M371C and
A399C mutant hDATs with MTSET caused a profound reduction in [3H]dopamine
uptake (Norregaard et al., 2003). Cocaine, but not dopamine, protected A399C
DAT from MTSET-induced inactivation. On the other hand, dopamine, and not
cocaine protected M371C from MTSET. This observation may imply that A399 is
in the DAT binding site of cocaine or that cocaine induces a conformational
change that diminishes the reactivity of A399C.

In addition, the finding that

protection of A399C occurs selectively with inhibitors and protection of M371C
selectively with substrates supports the notion that inhibitors promote and bind
conformational states of the transporter that differ from those adopted in the
presence of substrates (Norregaard et al., 2003).
Regarding other ECL mutations, WIN 35,428 affinity decreased 5-fold as a
result of the ECL 4 rDAT F390A mutation; dopamine uptake was virtually
eliminated (Lin et al., 1999). Asparagine substitution of hDAT D476, a residue at
the ECL 5 / TM 10 border, decreased WIN 35,428 affinity 4-fold, cocaine DUIP 3fold, and apparent affinity (measured by Km value) for dopamine 7-fold (Chen et
al., 2001). For the above ECL loop mutants, it is likely that the inhibitor binding
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affinity and uptake inhibition potency losses are due to mutation-induced
conformational changes; however, modifications in the actual inhibitor binding
sites have not been ruled out.

c. Intracellular loops (ICL)
The tyrosine residue at position 335 of the hDAT may be important for
cocaine binding. Mutation of this residue to alanine (Y335A) caused defects in
the function of high affinity Zn2+ binding to DAT (Loland et al, 2002). Zn2+ binding
to WT DAT normally reduces dopamine uptake. In Y335A DAT, binding of Zn2+
to its high affinity sites resulted in potentiation of dopamine uptake. In addition,
Y335A mutation caused a 150-fold reduction in apparent affinity of DAT for
cocaine and related inhibitors when compared with WT DAT values. Loland and
colleagues proposed that Y335 may be part of a network of intramolecular
interactions that is important for stabilizing the transporter in a conformational
state that maintains the structural integrity of the inhibitor binding site and to
which extracellular substrate can bind and initiate transport. Further analyses of
the intracellular loops of hDAT identified other residues that, when mutated to
alanine, exhibited similar phenotype as Y335A (Loland et al, 2004).

Akin to

Y335A, the mutants K264A (IL2), D345A (IL3), and D436A (IL4) were
characterized by lower affinities for cocaine and other inhibitors as well as a low
uptake capacity that was potentiated by Zn2+.

In a separate study, Chen et al,

2004 showed that D345N DAT also exhibited a phenotype similar to Y335A.
D345N mutation decreased cocaine analog binding by over 90% but uptake
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inhibition by various DAT inhibitors was preserved in contrast to what was
observed with Y335A mutation.

4. Regulation of DAT Function
a. Post-translational modification
DAT function is regulated largely by way of rapid shuttling of DAT to and
from the plasma membrane. Phosphorylation of DAT by kinases leads to rapid
redistribution and internalization of DAT away from the plasma membrane
causing diminished cellular uptake of dopamine (Pristupa et al., 1998, Melikian
and Buckley, 1999; Daniels and Amara, 1999). There are several consensus
sites on the primary structure of the DAT for protein kinase phosphorylation of
the transporter (Giros et al., 1992). Acute exposure of hDAT expressing Sf9 cells
to PMA, a PKC activator, reduced Vmax for [3H]dopamine uptake by ~ 40%
when compared with control cells treated with αPDD (an inactive phorbol ester)
(Pristupa et al., 1998).

This inhibition of uptake was blocked by the protein

kinase inhibitor staurosporine (Pristupa et al., 1998).

Furthermore, confocal

microscopy data revealed that the observed decline in [3H]dopamine uptake was
associated with redistribution of surface DAT to the internal environment.
Recruitment of the internalized transporters back to the cell surface was
responsible for the observed augmentation in [3H]dopamine uptake in cells
treated with the PKC inhibitor (Pristupa et al., 1998). Nonetheless, proof that the
direct phosphorylation of the transporter modifies its intrinsic activity or triggers
the downregulation and internalization of the dopamine transporter is
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inconclusive. The deletion of all the consensus sites for protein kinase C did not
put a stop to protein kinase C-induced internalization (Chang et al., 2001). In a
different study, deletion of the first 22 amino acids (N-terminus) from DAT
eliminated
al., 2003).
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P incorporation into DAT in response to PKC activation (Granas et
This shortened mutant DAT still transported substrate and was

internalized normally subsequent to protein kinase C activation (Granas et al.,
2003).

These data mean that N-terminal phosphorylation of DAT is not

necessary for transporter internalization.

Recent evidence indicates that the

transport capacity and intracellular trafficking of DAT is controlled by mitogenactivated protein kinase (MAPK) (Moron et al., 2003).

Incubation of striatal

synaptosomes or epitope-tagged hDAT HEK 293 cells with MAPK kinase
inhibitors diminished dopamine uptake in a concentration dependent manner;
decreased Vmax for dopamine uptake but had no effect on dopamine uptake
affinity (Moron et al., 2003).

Biotinylation and confocal microscopic studies

showed that the observed effect of MAPK kinase inhibitors on dopamine
transport kinetics was due to clathrin-mediated redistribution of hDAT from the
plasma membrane to the internal environment of the cell (Moron et al., 2003).
It has been demonstrated recently that PKC can control MAPK activation
and that the mechanism of activation shows isotype specificity (Schonwasser et
al., 1998). Some species of PKC, such as PKC-α, show an ability to activate the
MAPK cascade via c-Raf, while other isoforms activate this cascade by a
mechanism independent of c-Raf1 activation. Thus, distinct subclasses of PKC
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may account for two independent signalling pathways to MEK and, hence, MAPK
activation.

b. Protein-protein interactions
Monoamine transporters have sequence motifs that are known to guide
protein-protein interactions, including a leucine repeat in TM 2, a PDZ binding
site at the extreme carboxyl termini, and presumed tyrosine-based and di-leucine
internalization motifs (Torres et al., 2003). By means of the yeast two-hybrid
system, a direct interaction between α-synuclein and DAT has been determined
(Lee et al., 2001). α-synuclein is a pre-synaptic protein that has been associated
with Parkinson’s disease (Gwinn- Hardy, 2002).

α-synuclein augments the

functional activity of DAT when it is co-expressed with DAT in cells (Lee et al.,
2001). On the contrary, coexpression of α-synuclein and DAT in Ltk– fibroblasts
manifestly decrease the reuptake of dopamine by DAT by ~30–50% (Wersinger
and Sidhu, 2003; Wersinger et al., 2003; Sidhu et al., 2004). The diminution in
DAT activity was due to a reduction in Vmax for dopamine uptake by the
transporter without any change in DAT expression levels. An outcome of the αsynuclein-mediated reduction of DAT activity was that upon exposure of
cotransfected cells to dopamine, there was decreased dopamine-induced
oxidative stress and cytotoxicity. In the presence of α-synuclein, the DAT was
trafficked away from the plasma membrane into the cytoplasm. This is evident
from biotinylation experimental data showing reduced DAT presence at the
plasma membrane by (Wersinger et al., 2003). α-Synuclein interacts directly with
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DAT, creating a stable protein: protein heteromeric complex in cotransfected
cells, mesencephalic neurons, and substantia nigra. The interactions were
observed between the nonamyloid β component (NAC) domain (residues 58107) of α-synuclein and the last 22 amino acids of the carboxyl terminal tail of
DAT (Wersinger et al., 2003).

Analogous to wild-type, the missense A30P

mutant form of α-synuclein decreased DAT function, trafficking DAT away from
the plasma membrane and contributing to the formation of stable protein: protein
complexes, again through the NAC domain (residues 58-107) of A30P and the
last 22 amino acids of the CT tail of DAT (Wersinger et al., 2003a). The other
missense A53T mutant was unable to alter DAT function, and succeeding studies
demonstrated that this protein interacted only weakly with the transporter
(Wersinger et al., 2003a).
The PDZ domain-containing protein PICK 1 has been shown to interact
with the carboxyl termini of DAT and NET (Torres et al., 2001). In culture, PICK
1 colocalizes with DAT and NET in dopaminergic and noradrenergic neurons
respectively.

PICK 1 additionally stimulates DAT and NET clustering in

transfected cells thereby increasing the activity of the transporters. Thus, PICK 1
may play a part in targeting of these transporters to the nerve terminals (Torres
et al., 2001). In cultured neurons, a DAT mutant lacking the PICK 1 binding site
failed to localize to neuronal processes and remained confined primarily in cell
bodies. There are indications that PICK 1 interacts with PKC. It is possible then
that PICK 1 may be involved in the PKC-mediated trafficking of monoamine
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transporters. Recent experience also suggest an interaction between DAT and
the LIM homeodomain-containing protein, Hic-5 (Carneiro et al., 2002).

c. Transporter oligomerization
The oligomerization of DAT has been well studied and there are indications
that DAT function is also regulated via transporter oligomerization.

In

mammalian cells co-expressing differentially tagged DAT molecules, HA-tagged
DAT co-purified with 6His-tagged DAT signifying a physical contact between
transporter proteins (Torres et al., 2003).

Verification of the functional

oligomerization of DAT was achieved using dominant-negative mutants of DAT.
Two loss-of-function mutant transporters (Y335A and D79G) that were expressed
at the cell surface blocked wild-type DAT uptake activity without affecting the
membrane targeting of the wildtype transporter.

Furthermore, non-functional

amino and carboxyl termini-truncated mutants of DAT blocked wild-type DAT
function by impeding the normal processing of the wild-type transporter to the cell
membrane (Torres et al., 2003). Mutations in the leucine repeat of the second
transmembrane domain of the transporter removed the dominant-negative effect
of all these mutants. Additionally, a small fragment comprising the first two
transmembrane domains of DAT blocked wild-type transporter function but not
when the leucine repeat motif was mutated. Taken together, these results
indicate that the assembly of DAT monomers plays a vital role in the expression
and function of the transporter (Torres et al., 2003). Hastrup et al., 2001 have
also identified a well characterized dimerization motif, GxxxG, in the intracellular

32
half of TM 6 of DAT. DAT dimers are formed as a result of a symmetrical crosslinking between cysteine residues located on the extracellular face of TM 6. The
precise contribution of oligomer formation to transporter function remains
uncertain. Nonetheless, oligomerization has clearly been established to play a
role in facilitating the trafficking of the transporters to the surface. Data from
Javitch’s (Hastrup et al., 2001) and Caron’s research groups (Torres et al., 2003)
have shown that mutants in which the domains involved in oligomer formation
have been mutated are not efficiently delivered to the cell surface.
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II. MATERIALS AND METHODS

A. Materials and Equipment
1. Facilities
Laboratories – Mellon Hall of Science, Room 456
Office – Mellon Hall of Science, Rooms 420 and 456
2. Cell lines
Chinese Hamster Ovary (CHO) cells stably expressing wildtype and D79E
mutant DAT.
COS 7 cells
3. Chemicals and Drugs
Bovine serum albumin
Fisher Scientific, Pittsburgh, PA
Complete Mini protease inhibitor cocktail tablets
Roche Diagnostics Corp., Indianapolis, IN
Compressed carbon dioxide
Air Products, Pittsburgh, PA
Dimethylsulfoxide
Sigma Chemical Co., St. Louis, MO
Ampicillin Na salt
Fisher Scientific, Pittsburgh, PA
Ethanol, HPLC grade
Fisher Scientific, Pittsburgh, PA
Isopropanol, DNase-free
Fisher Scientific, Pittsburgh, PA
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LB agar
Fisher Scientific, Pittsburgh, PA
LB broth
Fisher Scientific, Pittsburgh, PA
Methanol, HPLC grade
Fisher Scientific, Pittsburgh, PA
Ribonuclease A
Fisher Scientific, Pittsburgh, PA
Precast polyacrylamide gels, 4 – 20%
BioRad Laboratories, Hercules, CA
dNTP mix
Stratagene, La Jolla, CA
Plasmid mini-prep kit
Stratagene, La Jolla, CA
Polymerase, Pfu Turbo
Stratagene, La Jolla, CA
Quickchange mutagenesis kit
Stratagene, La Jolla, CA
XL1 Blue cells
Stratagene, La Jolla, CA
Dpn1 enzyme
Stratagene, La Jolla, CA
Plasmid maxi-prep kit
Qiagen Inc., Valencia, CA
Plasmid mini-prep kit
Qiagen Inc., Valencia, CA
Qiaquick gel extraction kit
Qiagen Inc., Valencia, CA
Qiaquick PCR extraction kit
Qiagen Inc., Valencia, CA
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D-glucose
Sigma Chemical Co., St. Louis, MO
Tetracycline-HCL
Sigma Chemical Co., St. Louis, MO
F-12 Nutrient Mixture
GIBCO-BRL, Grand Island, NY
Glycine
Sigma Chemical Co., St. Louis, MO
HEPES
Fisher Scientific, Pittsburgh, PA
HRP-conjugated goat anti-rat IgG
Chemicon International, Temecula, CA
Agarose
Invitrogen, Carlsbad, CA
Alexa-Fluor 488, goat anti-rat IgG (H+L)
Molecular Probes, Eugene, OR
MAB369 Rat anti-Dopamine Transporter
Chemicon International, Temecula, CA
DH5α cells
Invitrogen, Carlsbad, CA
PolyFect Transfection Reagent
Qiagen Inc., Valencia, CA
SOC media
Invitrogen, Carlsbad, CA
Not 1 restriction enzyme
Invitrogen, Carlsbad, CA
Bgl2 Restriction Enzyme
Invitrogen, Carlsbad, CA
Psh1 restriction enzyme
Invitrogen, Carlsbad, CA
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BsiW1 restriction enzyme
Invitrogen, Carlsbad, CA
Rhodamine phalloidin
Molecular Probes, Eugene, OR
T4 DNA ligase
Invitrogen, Carlsbad, CA
Penicillin-Streptomycin
GIBCO-BRL, Grand Island, NY
Fetal bovine serum
GIBCO-BRL, Grand Island, CA
Sodium Dodecyl Sulfate
Sigma Chemical Co., St. Louis, MO
Sodium Hydroxide
Sigma Chemical Co., St. Louis, MO
Trichloroacetic Acid
Sigma Chemical Co., St. Louis, MO
Trizma Base
Sigma Chemical Co., St. Louis, MO
Trypsin-EDTA 10X
GIBCO-BRL, Grand Island, NY
ScintSafe scintillation fluid
Fisher Scientific, Pittsburgh, PA
PBS, Ca/Mg-free
Fisher Scientific, Pittsburgh, PA
Tris-HCL salt
Sigma Chemical Co., St. Louis, MO
Protein MW marker
Fisher Scientific, Pittsburgh, PA
Sodium chloride
Sigma Chemical Co., St. Louis, MO
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[3H]WIN35, 428
Perkin Elmer, Foster City, CA
[3H]Dopamine
Perkin Elmer, Foster City, CA
GVA Mounting Solution
Zymed, San Francisco, CA
Goat Serum
Biomeda, Foster City, CA
4. Materials
BioRad Protein Assay Kit
BioRad, Hercules, CA
Cryogenic vials
Nalgene, Rochester, NY
Polaroid Film
Fisher Scientific, Pittsburgh, PA
Pasteur pipettes
Fisher Scientific, Pittsburgh, PA
Scintillation vials
Fisher Scientific, Pittsburgh, PA
Test tubes, 12x75mm
Fisher Scientific, Pittsburgh, PA
PVDF membrane
BioRad Laboratories, Hercules, CA
Sterile Tissue culture plates (6-, 12-, 24-well)
Fisher Scientific, Pittsburgh, PA
Sterile disposable serological pipettes (5, 10, 25 ml)
Fisher Scientific, Pittsburgh, PA
Eppendorf tubes (1.5µl)
Fisher Scientific, Pittsburgh, PA
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Glass microscope coverslips (#1)
Fisher Scientific, Pittsburgh, PA
Glass microscope slides
Fisher Scientific, PA
Kodak T-Max 400 film
Eastman Kodak Co., Rochester, NY
Fisherbrand Redi-TipsTM disposable pipette tips (1, 10, 200, 1000µl)
Fisher Scientific, Pittsburgh, PA
Pipette Aid
Drummond Scientific Company, Broomall, PA
5. Equipment
Accumet pH meter, Model 291
Fisher Scientific, Pittsburgh, PA
BioRad Power Pac 3000
BioRad, Hercules, CA
Hot plate with stirrer
Fisher Scientific, Pittsburgh, PA
Leica Confocal Laser Microscope TCS-SP2
Leica Microsystems, San Diego, CA
Liquid Scintillation Counter Tri-Carb 2100TR
Packard Instrument Co., Downers Grove, IL
UV/VIS Spectrophotometer DU530
Beckman Instruments, Fullerton, CA
Analytical Balance
Mettler-Toledo Inc., Highstown, NJ
Centrifuge 5810R (Large)
Eppendorf North America Inc., Westbury, New York.
Centrifuge 5415C (Small)
Eppendorf North America Inc., Westbury, New York.
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Universal Vacuum System UVS400
Savant Company Inc., Irvine, CA
PCR Mastercycler
Eppendorf North America Inc., Westbury, New York.
Weighing Balance
Denver Instrument, Denver, CO.
Freezer (-20oC)
Forma Scientific, Waltham, MS
Liquid Nitrogen Tank
Laboratory Refrigerator
REVCO Thermo Electron Corporation, Asheville, NC.
Horizontal Gel Electrophoresis System
GIBCO-BRL, Grand Island, NY.
Gel Apparatus
BioRad, Hercules, CA.
6. Computer Software
GraphPad Prism 3.0
GraphPad, San Diego, CA
Microsoft Excel, Microsoft Office 2003
Microsoft Corporation, Orem, UT
Microsoft Word, Microsoft Office 2003
Microsoft Corporation, Orem, UT
Adobe Photoshop Version 5.0
Adobe Systems, Seattle, WA
Adobe Acrobat (Reader and Writer)
Adobe Systems Inc., Seattle, WA
MDL-ISIS Draw 2.5
Elsevier MDL, San Leandro, CA
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B. Methodology and Procedures
1. Cell culture
CHO-K1 cells stably transfected with WT DAT or D79E DAT were used in
the present study.

These cells were grown at 37OC and 5% CO2 in F12K

medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml
penicillin, 100mg/ml streptomycin and 100µg/ml G-418.

COS-7 cells were

employed for all experiments requiring transient transfection of plasmid DNA.
The COS-7 cells were maintained in DMEM media supplemented with 10% FBS,
100 units/ml penicillin, 100mg/ml streptomycin, and 20 mM L- glutamine. All cells
were grown in 75 cm2 flasks and subcultured twice weekly.

Cells were

subcultured by aspirating media from the flask and washing the confluent
monolayer with 10 mL Hanks buffered salt solution (HBSS). The cells were then
detached by addition of 3 mL trypsin-EDTA solution to the monolayer.

The

trypsin-EDTA solution was swirled to coat the monolayer and 2 mL of the trypsinEDTA was aspirated from the flask.

The cells were left to stand at room

temperature (under a sterile hood) in 1 mL trypsin-EDTA for 3 min or until the
cells detach from the flask. The trypsinization reaction was quenched by addition
of 9 mL of appropriate “complete media” (media supplemented with FBS and
antibiotics). The trypsinate was gently mixed to create an even suspension of
cells.

Two milliliters, out of a total volume of 10 mL, of the trypsinate was

transferred into a new flask and 18 mL of “complete media” was added to it; the
cell solution was then mixed gently. The flask was capped and kept flat in the
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incubator (37oC and 5% CO2) and cells were allowed to grow to confluence.
Cells were typically subcultured on Mondays and Thursdays.

2. Site- directed mutagenesis
All site-directed mutagenesis was conducted using the QuikChange
mutagenesis kit (Stratagene). rDAT in Bluescript vector was used as template
for the PCR-based mutagenesis. Sense and antisense oligonucleotides were
designed to contain the desired mutations. The oligonucleotide primers were
synthesized by Sigma-Genosys Inc., U.S.A. The sequences of primers used for
the

generation

of

D79L

DAT

were:

5’-

GTCATCGGCTTTGCTGTGCTCCTGGCCAATGTCTG-3’ for the forward primer
and

5’-CCAGACATTGGCCAGGAGCACAGCAAAGCCGATGAC-3’

for

the

reverse primer. These complementary primers were annealed to the template
cDNA and extended with the proofreading polymerase pfu Turbo (Stratagene)
with the following PCR parameters: 30 sec at 95oC, 30 sec at 95oC, 1 min at
55oC, and 6 min at 72oC for 25 cycles. Subsequently, the PCR product was
digested with Dpn1 to eliminate the methylated, nonmutated parental strands.
The mutant cDNA was then transformed into XL1-Blue supercompetent E. coli
cells using the heat-shock method. The bacterial cell solution was then plated on
agar plates containing 50 µg/ mL ampicillin and incubated overnight at 37oC.
The following day, colonies were selected and plasmid preparation was carried
out using the Stratagene miniprep system to produce pure supercoiled plasmid
DNA. Mutagenesis was confirmed by DNA sequence analysis of the miniprep
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product (University of Pittsburgh sequencing facility). The fragment (~ 500 bp)
containing the mutation in rDAT-pBluescript was isolated by digestion with Not1
and Bgl2 restriction enzymes, gel purified, and ligated into the Not1/Bgl2digested wild type rDAT-pC1 vector. The ligation product was transformed into
MC1061 cells using the heat shock method and cells were plated on agar plates
containing ampicillin and tetratcycline and incubated overnight at 37oC.
Colonies were again selected and the plasmid DNA was purified using the
Stratagene mini-prep kit according to manufacturer’s guidelines. The fragment
containing the mutation in rDAT-pC1 was isolated by double digestion with
PshA1 and BsiW1 enzymes. This 1.8 kb fragment was then ligated into the
PshA1/BsiW1- digested wildtype rDAT-pIRES vector. The ligation product was
transformed into DH5α supercompetent E. coli cells by way of the heat shock
method and cells were plated on agar plates containing ampicillin. The agar
plates were then incubated overnight at 37oC to allow growth of bacterial
colonies. A few bacterial colonies were selected, lysed, and the supercoiled
DNA was purified using the Stratagene mini-prep kit.

The presence of

supercoiled plasmid DNA was verified by agarose gel electrophoresis. Following
confirmation of successful mutagenesis by DNA sequence analysis, a sample
from the mini-prep product was again transformed into DH5α cells, plated on
agar plates and incubated overnight at 37oC. Plasmid preparations were carried
out, this time, using the Qiagen maxi-prep kit to produce a larger volume of pure
supercoiled plasmid DNA sufficient for transient transfection of cells. The DNA
concentration and purity (measured as A260:A280 ratio) were estimated by
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spectrophotometric analysis. Plasmid DNA having an A260:A280 ratio greater than
or equal to 1.7 was typically used for transient transfection of COS 7 cells. All
other D79 mutant DATs used in the present study were previously generated by
Wenfei Wang in the laboratory of Dr. Surratt at Albert Einstein College of
Medicine (AECOM), Bronx, New York.

3. Cell Transfections
A modification of the calcium phosphate method or the use of PolyFect
reagent (Qiagen, Los Angeles, CA) was employed for transient transfections of
COS 7 cells. For the calcium phosphate method, confluent COS 7 cells were
subcultured in 6-well plates such that the monolayer would be 40 - 50% confluent
when the transfection commenced the next day. Twenty micrograms of plasmid
were used for the transient transfections. Two tubes were prepared, with the
contents of one tube slowly added to the second tube. The first tube contained
plasmid DNA, Millipore water, 10x Tris- EDTA (TE) buffer pH 8.0, and 0.5M
CaCl2 mixed together to achieve a final amount of DNA of 20 µg. The second
tube contained 2x HEPES- buffered saline (HBS) solution. The contents of the
first tube were added to the second tube dropwise with continuous vortexing. For
an individual well of the 6-well plate containing 40% confluent cells, 200 µl of the
above mixture was added.

The cells take up the exogenous plasmid via

endocytosis of the calcium phosphate/DNA complex.

On the next day, the

transfection mixture is removed and the replaced with 2 ml fresh DMEM. The
cells were used for pharmacological studies 48 hours later.
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For the PolyFect reagent-mediated transient transfection, a slight
modification of the manufacturer’s protocol was employed.

The day before

transfection, cells were seeded in 6-well plates and incubated overnight at 37OC
and 5% CO2 such that the cells will be 50-80% confluent the next day. On the
day of transfection, cell monolayers in 6-well plates were washed with 1 x 1mL
phosphate buffered saline (PBS), pH 7.3, and 1.5 mL of “complete” DMEM media
was added to each well. These cells were then incubated at 37oC and 5% CO2
until the commencement of transfection. The transfection mixture was prepared
as follows: plasmid DNA (1.5 µg) was diluted with 100 µL of DMEM containing no
serum, proteins, or antibiotics and mixed by vortexing for 10 seconds.

Ten

microliters of PolyFect transfection reagent was then added to the DNA solution,
mixed by vortexing for 10 sec, and incubated at room temperature for 8 min to
allow DNA-PolyFect complex formation.

Subsequently, 600 µL of complete

DMEM (containing serum and antibiotics) was added to the reaction tube
containing the transfection complexes and mixed by pipetting up and down twice.
The total volume of the transfection mixture was immediately transferred to a
single well of the 6-well plate containing 80% confluent cells at room
temperature. The transfected cells were incubated at 37oC and 5% CO2 and
used for pharmacological studies 48 hours after transfection. When performing
transient transfections of cells in more than one well (which was more often the
case), the volumes described above were multiplied by the number of wells used.
The stably-transfected DAT-CHO cell lines used in this study were
prepared in the laboratory of Dr. Surratt at AECOM, New York. Lipofectamine-
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mediated transfection was used to prepare the stable cell lines; stable
transfectants were selected in the presence of 500 µg/ml G-418 in F-12K HAM
medium. Cell lines were maintained as described above.

4. Immunocytochemistry and confocal microscopy
COS-7 cells were seeded on coverslips placed in 6-well plates and grown
to 40 - 60% confluence. Cells were transiently transfected on the following day
with WT or D79 mutant DAT plasmids, or the vector control plasmid, using
PolyFect reagent (Qiagen, Los Angeles, CA). After 48 hours, cells were fixed in
4% paraformaldehyde solution in PBS at room temperature for 15 min, rinsed
once with PBS, and incubated with blocking-permeabilizing solution (5% goat
serum, 1% BSA, and 0.1% Triton X-100 in PBS buffer solution) for 45 min at
room temperature.

Cells were next incubated with rat monoclonal anti-DAT

antibody (MAB369; Chemicon, Temecula, CA) at 1:1000 dilution for 1 hr. The
anti-DAT antibody solution was aspirated and cells were washed five times with
PBS containing 0.1% Triton X-100 (TPBS), and incubated with a mixture of
secondary antibody (goat anti-rat Alexa Fluor 488; Molecular Probes, Eugene,
OR) at 1:500 dilution and rhodamine phalloidin (Molecular Probes) at 1:250
dilution for 1 hr. After three washes in TPBS followed by two washes in PBS,
coverslips were mounted on slides using GVA mounting solution (Zymed, San
Francisco, CA) and left to dry overnight in the dark at 4OC. DAT protein was
visualized using the Leica TCS-SP2 confocal laser microscope with a glycerin
immersion 63x objective.

Alexa 488 was excited at 488 nm with an
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argon/krypton laser and emission photons from 500 – 600 nm were accumulated
by the photomultiplier tube. Rhodamine phalloidin was excited at 543 nm with a
helium/neon laser and emission photons from 550 to 650 nm were accumulated.
The fluorophores were detected separately and overlay images were generated
automatically by the imaging software.

5. [3H]-Dopamine saturation uptake assays
All [3H]-dopamine uptake assays were conducted with cell monolayers
seeded in 6-well plates. In dopamine saturation uptake assays, cell monolayers
in six-well plates were washed 2 X 1 mL with KRH buffer (25mM HEPES, pH 7.3,
125 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM KH2PO4, and 5.6 mM
glucose) supplemented with 50 mM ascorbic acid (KRH/AA) and then incubated
with increasing concentrations (0.5 – 16 µM) of a fixed ratio of [3H]dopamine:
nonradioactive dopamine (~0.1 Ci/mmol) for 5 min.

Dopamine uptake was

quenched by aspirating the dopamine solution and washing the monolayers with
2 X 1 mL KRH/AA buffer. Subsequently, cells in each well were lysed with 1 ml of
1% SDS, incubated at room temperature for 1 hr with gentle shaking, and
transferred to scintillation vials for determination of incorporated tritium.

The

results of liquid scintillation counting and protein determinations were used to
calculate uptake of [3H]dopamine expressed as pmol/mg protein/ min. In each
experiment, the mean result from duplicate wells for each treatment was used
and the experiments were repeated at least four times. Specific uptake was
calculated as the difference between uptake of [3H]dopamine in the absence and
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presence of 10 µM mazindol. KM and VMAX values were calculated from nonlinear regression analysis of the data for each individual experiment using the
GraphPad Prism 3.0 software.

6. [3H]-Dopamine uptake inhibition assays
The monolayer was washed twice with KRH/AA buffer (2 x 1 mL).
Dopamine uptake inhibition experiments incubated the cells with inhibitors for 10
minutes, followed by the addition of 10nM [3H]-dopamine for a further five
minutes. The range of concentrations of inhibitors or substrates employed was
as follows: cocaine, 1 nM - 100 µM; WIN35,428, 1 nM - 10 µM; 8-oxanorcocaine, 1 nM - 1 mM; 4-ARA-127, 10 nM - 100 µM; mazindol, 3 nM - 10 µM;
methylphenidate, 3 nM - 10 µM; benztropine, 0.1 nM - 30 µM; 3β-4'chlorobenztropine, 1 nM - 30 µM; 4'-chlorobenztropine, 0.1 nM - 30 µM; 4',4"difluorobenztropine, 0.1 nM - 10 µM; GBR-12,909, 0.1 nM - 10 µM; rimcazole, 1
nM - 30 µM; N-formyl-4,4'-difluorobenztropine, 10 nM - 1 mM; and 4trifluoromethylbenztropine, 1 nM - 30 µM. Uptake was quenched by aspirating
the inhibitor/ radioligand solution and washing the monolayer with 2 x 1 ml of
KRH containing ascorbic acid (KRH/AA). Nonspecific binding was assessed with
10µM mazindol, or with 30 µM cocaine if the drug tested was mazindol. The
cells in each well were then lysed with 1 mL of 1% SDS and incubated at room
temperature for 1 hour with gentle shaking.

The lysate was transferred into

scintillation vials containing 5 mL ScintSafe fluid and radioactivity was counted
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using a liquid scintillation counter. Ki values for [3H]dopamine uptake inhibition
were determined with GraphPad Prism 3.0.

7. [3H]WIN35,428 saturation binding assays
All binding assays were conducted with stable DAT-CHO cells or transient
DAT-COS 7 cells subcultured in six-well plates.

[3H]WIN35,428 was the

radioligand used in all binding assays. This compound is structurally similar to
cocaine, labels both the high- and low- affinity binding sites just as cocaine, but is
more stable in vitro.

For [3H]WIN35,428 saturation binding assays, serial

dilutions of WIN35,428 (1 nM - 10 µM) were made in KRH/AA buffer.
[3H]WIN35,428 was added to each dilution of drug to achieve a final
concentration of approximately 1 nM for the radioligand. Cell monolayers in 6well plates were then washed with 2 x 1mL of KRH/AA buffer and incubated with
the mixture of [3H]WIN35,428 and WIN35,428 for 15 minutes. The drug solution
was removed and the cell monolayers were washed with 2 x 1 mL KRH. Cells
were lysed with 1% SDS solution and the 3H content of the cell lysates was
determined in a scintillation counter.

Bmax and Kd values for [3H]WIN35,428

binding were determined with GraphPad Prism 3.0 software.

8. [3H]WIN35,428 binding inhibition assays
All competition binding assays were conducted exactly as described for
the dopamine uptake inhibition assays except that [3H]-dopamine was replaced
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with 1nM [3H]WIN35,428 and cells were incubated with a mixture of radioligand
and nonradioligand competitor for 15min. Briefly, serial dilutions of the drugs to
be examined were made in KRH/AA buffer. [3H]WIN35,428 was added to each
dilution of drug to achieve a final concentration of 1 nM for the radioligand. The
range of concentrations of drugs employed were as

indicated above for

dopamine uptake inhibition: cocaine, 1 nM - 100 µM; WIN35,428, 1 nM - 10 µM;
8-oxa-norcocaine, 1 nM - 1 mM; 4-ARA-127, 10 nM - 100 µM; mazindol, 3 nM 10 µM; methylphenidate, 3 nM - 10 µM; benztropine, 0.1 nM - 30 µM; 3β-4'chlorobenztropine, 1 nM - 30 µM; 4'-chlorobenztropine, 0.1 nM - 30 µM; 4',4"difluorobenztropine, 0.1 nM - 10 µM; GBR-12,909, 0.1 nM - 10 µM; rimcazole, 1
nM -30 µM; N-formyl-4,4'-difluorobenztropine, 10 nM - 1 mM; and 4trifluoromethylbenztropine, 1 nM - 30 µM). To begin with, cell monolayers in 6well plates were washed with 2 x 1mL of KRH/AA buffer and incubated with the
mixture of radioligand and nonradioactive competitor for 15 minutes.

The

experiment was quenched by aspirating the test solution and washing the cell
monolayers twice (2 x 1 mL) with KRH/AA buffer.

Nonspecific binding was

assessed by addition of 10µM mazindol except when mazindol was the drug
tested, in which case 30µM cocaine was substituted. The cell monolayers were
then lysed with 1 mL of 1% SDS solution and incubated at room temperature for
1 hour with gentle shaking. Cell solution from each well was then transferred to
scintillation vials containing 5 mL of ScintSafe fluid and radioactivity was counted
using a scintillation counter.
GraphPad Prism 3.0 software.

Ki, Kd, and BMAX values were determined with
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9. Protein assays
Stable DAT-CHO cells or transient DAT-COS 7 cells subcultured in 6-well
plates were used for protein assays.

For every experiment carried out that

required estimates of protein content, two wells were reserved for this purpose.
The confluent cell monolayers in 6-well plates were washed with 2 x 1 mL PBS.
Cells in each well were then lysed with 0.5 mL of 0.2N NaOH solution, scraped
with a rubber policeman, and incubated for 30 min at 4oC with gentle shaking.
The cell lysates were transferred into Eppendorf tubes for storage at -20oC or for
immediate estimation of protein content.

Protein assays were conducted

according to the method of Bradford. For each assay, carried out in duplicate,
780 µL of water was added to 20 µL of cell lysate in a test tube and mixed gently.
200 µL of BioRad “micro-Bradford” reagent was then added to the cell solution,
vortexed for 10 sec, and incubated at room temperature for 5 min.

The

absorbance of the protein/ dye solution was measured at 595 nm using a
spectrophotometer. The concentration of protein was calculated by interpolating
the absorbance reading of the sample protein using protein standard curve.
This curve was generated using BSA (1mg/mL stock solution) as protein
standard. A serial dilution of the BSA stock solution in water was performed to
make six different concentrations of BSA such that the final concentrations were
1, 2, 3, 4, 5, and 6 µg/ mL. The initial volume for each dilution was 800 mL (e.g.
for 2µg/ mL: 2µL of 1mg/mL BSA + 798 µl of water). 200 µL of BioRad reagent
was then added to each test tube containing the protein dilutions (bringing the
total volume of reaction to 1 mL), vortexed for 10 sec, and incubated at room
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temperature for 5 min. The absorbance of each protein dilution was read at 595
nm using a spectrophotometer. A protein standard curve (plot of absorbance
versus amount of protein) was generated using the Excel software.
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III. RESULTS AND DISCUSSION

A. Results
1. Expression, localization and function of WT DAT and D79 mutant DATs
WT DAT and four D79 mutant DATs (D79A, D79E, D79L, D79N) were
screened for their abilities to bind [3H]WIN35,428, take up [3H]dopamine, or
target to the cell membrane.

The mutant DATs were made by site-directed

mutagenesis and confirmed by DNA sequencing. These mutants were used to
characterize features of the TM1 aspartic acid residue important for dopamine
uptake and inhibitor recognition. A mutation from aspartate to alanine (D79A)
results in a large decrease in size and a loss of charge and polarity of the
residue.

The mutation of aspartate 79 in rDAT to glutamate (D79E) is a

conservative exchange as these two amino acids differ from one another only by
one methylene group. The D79L mutation provides a leucine side chain that
causes a loss in the negative charge and hydrogen bonding potential of
aspartate but retains a size similar to that of aspartate.

An asparagine for

aspartate substitution at position 79 of DAT (D79N) eliminates the negative
charge but retains the hydrogen bonding potential of the residue. All constructs
were assessed in parallel using a one point binding assay. Relative to WT DAT,
only

the

D79E

DAT

mutant

displayed detectable specific binding of

[3H]WIN35,428 (P<0.05, compared with vector transfected cells) (Fig. 3).
The D79 mutant DATs were also tested for functional uptake by incubating
COS 7 cells transiently transfected with the cDNA of WT DAT or the D79 mutant
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DATs with 10 nM [3H]dopamine for 5 min at 22oC. The D79E DAT mutant was
yet again the only mutant DAT that displayed functional uptake of [3H]dopamine
(P<0.001, compared with vector-transfected cells) (Fig. 4).

Figure 3. Determination of [3H]-WIN35,428 specific binding by COS-7 cells expressing WT
or D79 mutant DAT proteins.
The extent of specific [3H]-WIN35,428 binding as a percentage of WT DAT was assessed
for cells transiently transfected with plasmids encoding D79A, D79E, D79L or D79N DAT, or the
plasmid vector lacking DAT sequence (“Vec”). The data represent an average of 5 separate
experiments. * P < 0.05 (Student T test) relative to "vector alone" control. Reprinted with
permission from ASPET from Ukairo et al., 2005.
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Figure 4. Determination of [3H]-dopamine uptake ability by COS-7 cells expressing WT or
D79 mutant DAT proteins.
The extent of total [3H]-dopamine uptake as a percentage of WT DAT was assessed for
cells transiently transfected with plasmids encoding D79A, D79E, D79L or D79N DAT, or the
plasmid vector lacking DAT sequence (“Vec”). The data represent an average of 5 separate
experiments. *P< 0.001 (Student T test) relative to "vector alone" control.

Confocal microscopy experiments, however, showed that all the DAT
protein constructs tested were expressed at the cell surface (Fig. 5). Cell surface
expression of WT DAT and D79 mutant DAT proteins had earlier been confirmed
by biotinylation and western blotting data from our laboratory; D79N DAT,
nevertheless, displayed a diminished cell surface expression when compared to
WT DAT (Wang et al., 2003). The fact that all D79 mutant DATs were expressed
on the cell plasma membrane suggests that the functional and radioligand
binding deficits observed were not due to an inability to target to the cell surface.
Only the WT DAT and D79E DAT mutant were further characterized due to the
failure to detect either radioligand specific binding (Fig. 3) or [3H]-dopamine
uptake (Fig. 4) in the other mutant constructs.
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Figure 5. Localization of WT or D79 mutant DAT in DAT-COS 7 cells under confocal laserscanning microscope.
COS 7 cells transiently transfected with WT DAT or D79 mutant DAT were stained with
monoclonal anti-DAT antibody and visualized with Alexa Fluor 488 (green signal). The cells were
also stained with rhodamine phalloidin (red signal) to label cortical F-actin, a marker at the cell
membrane. Overlay view (yellow signal) shows the co-localization of WT DAT or D79 mutant DAT
with F-actin. Shown are representative confocal images of four different experiments. Scale bar =
8.00µm for all images. Reprinted with permission from ASPET from Ukairo et al., 2005.
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2. Assessing the role of DAT TM 1 D79 residue in dopamine uptake
The dopamine uptake inhibition potencies (DUIPs) and binding affinities
of various dopamine analogs at WT DAT and D79E DAT were tested. This study
investigated the effect of modifying the catechol moiety of dopamine to overall
substrate transport and also verified whether the D79 side chain of DAT was
involved in recognition of some feature of the substrate catechol ring moiety.
The drugs tested were: (+)-amphetamine, (-)-amphetamine, p-tyramine, mtyramine, norepinephrine, and dopamine (Fig. 6).

OH
HO

NH2
H3 C

NH 2

HO

Amphetamine

HO

Norepinephrine
NH2

HO

Dopamine
HO
NH2

p-Tyramine

N H2

HO

m-Tyramine

Figure 6. Chemical structures of DAT substrates employed in [3H]-WIN35,428 and [3H]dopamine displacement assays.
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The Km for dopamine uptake and the Ki for dopamine inhibition of
[3H]WIN35,428 binding were unaffected by the D79E mutation (Table 1). These
data contradict the long-held hypothesis of an ionic interaction between
dopamine and aspartate-79 as being the principal means of interaction between
dopamine and the DAT. Norepinephrine (addition of a β-OH group to dopamine)
was equipotent at both WT DAT and D79E DAT at inhibiting dopamine uptake.
On the other hand, the D79E mutation caused a two-fold loss in the binding
affinity of norepinephrine (Table 1). The D79E mutation had little or no effect on
the DUIPs of m-tyramine or p-tyramine (each lacking one of the catechol OH
groups found in dopamine); the mutation, nevertheless, decreased the binding
affinities of both compounds by more than 5-fold (Fig 7, and Table 1). The D79E
mutation induced a 5-fold loss in the DUIP and a 9-fold loss in the binding affinity
of S(+)-amphetamine (lacking both catechol OH groups and adding an α–methyl
group) (Table 1). The DUIP of the less psychoactive R(-)-amphetamine isomer
was not significantly affected by the D79E mutation, but its binding affinity was
diminished by about 4-fold (Table 1). The DUIPs for m-tyramine, p-tyramine and
(-)-amphetamine at both DAT constructs suggest that loss of one or both
catechol OH groups was tolerated by D79E DAT, while the binding affinities of
the three substrates were markedly diminished by the mutation.
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A

C

B

D

Figure 7. m-Tyramine or p-Tyramine inhibition of [3H]-dopamine uptake or [3H]WIN35,428
binding.
The [3H]-dopamine uptake inhibiton (A and C) and inhibition of [3H]WIN35,428 binding (B
and D) experiments were done under identical conditions at CHO cells stably transfected with WT
DAT (filled symbols) or D79E DAT (open symbols). The data are representative of at least three
independent experiments.
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Table 1. Effect of DAT substrates on CHO cells stably expressing WT and D79E DAT.
KM and Ki values were derived from experiments incubating the stably transfected cells
with nonradioactive substrates in the presence of [3H]-dopamine or [3H]-WIN35,428 at 22OC in
KRH/AA buffer. Values are presented as mean ± S.E.M. for three to six independent
experiments. Reprinted with permission from ASPET from Wang, Sonders, Ukairo et al., 2003.

Ki or KM
WT DAT

D79E DAT
(µM)

3

a

[ H]- dopamine uptake
Dopamine
Norepinephrine
m-Tyramine

1.7 ± 0.3
5.4 ± 0.5a
1.4 ± 0.3

2.3 ± 0.3
5.2 ± 0.3a
1.2 ± 0.3a

p-Tyramine
(+)-Amphetamine
(-)-Amphetamine

1.7 ± 0.1
0.5 ± 0.1
2.8 ± 0.5

3.3 ± 0.4b
2.4 ± 0.3b
4.2 ± 0.5a

[3H]-WIN35,428 inhibition
Dopamine
Norepinephrine

2.1 ± 0.2
2.3 ± 0.5c

m-Tyramine
p-Tyramine
(+)-Amphetamine
(-)-Amphetamine

1.0 ± 0.2a
0.8 ± 0.1a,c
0.4 ± 0.1a
2.0 ± 0.2

2.5 ± 0.4
5.5 ± 0.7a,b
6.6 ± 1.2a,b,c
4.3 ± 0.5b
3.7 ± 0.8b
8.1 ± 0.5a,b,c

P<0.05 versus dopamine for the given assay and DAT construct (Student’s T test)
P<0.05 versus WT DAT for that assay (Student’s T test)
c
P<0.05 for [3H] for WIN inhibition versus dopamine uptake at the same DAT construct (Student’s
T test)
b
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3. Effect of DAT inhibitors on CHO cells stably expressing WT or D79E
DAT
WT DAT and D79E DAT stably-transfected CHO-K1 cell lines were
employed to characterize the DUIPs and binding affinities of various DAT
inhibitors (Fig 8). In order to better assess the key functional groups important
for DAT recognition, DAT inhibitors containing various pharmacophore
modifications of cocaine were selected for analysis. The Ki values for DUIP and
binding affinity were obtained from inhibition of [3H]-dopamine uptake and [3H]WIN35,428 binding inhibition experiments respectively; both assays were carried
out under the same conditions. Previously, it was shown that the D79E DAT
mutation had little or no effect on the DUIPs of the classical DAT inhibitors
cocaine, WIN35,428, methylphenidate and mazindol (Wang et al., 2003). Except
for benztropine (structurally different from cocaine by having a diphenylmethoxy
group at the C-3 position), all other drugs studied here displayed this same DUIP
pattern. The DUIP of 8-oxa-norcocaine, an analog of cocaine lacking the tropane
nitrogen and thus a positive charge, was unaffected by the D79E mutation (Table
2).

Furthermore, the DUIPs of 4-ARA-127, rimcazole and GBR-12909 (all

compounds containing the piperidine or piperazine substitution of the tropane
ring) were unaffected by the D79E DAT mutation (Fig. 9, and Table 2).

In

contrast, the DUIP of benztropine was 8 fold higher at D79E DAT than at WT
DAT, a deviation from the trend observed for the other drugs (Fig 9 and Table 2).
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Figure 8. Chemical structures of DAT inhibitors employed in [3H]-WIN35,428 and [3H]dopamine displacement assays.
Reprinted with permission from ASPET from Ukairo et al., 2005.
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The mutation had a different effect on the binding affinities of the drugs studied.
The binding affinities of cocaine, WIN35,428, 8-oxa norcocaine, mazindol, and
methylphenidate were about 3-8 fold less at D79E DAT when compared with WT
DAT values. The mutation had no effect on the binding affinities of GBR-12,909
and rimcazole but elevated the binding affinity of ARA-127 by 2-fold (Table 2).
As was earlier reported for cocaine, WIN35,428, methylphenidate, and mazindol,
the binding affinities for rimcazole and 8-oxanorcocaine were 3-6 fold higher than
their DUIPs at WT DAT. The binding affinities for 4-ARA-127 and GBR-12,909 at
WT DAT were 2 fold lower than their DUIPs (Table 2). On the other hand,
benztropine

was

equipotent

at

inhibiting

[3H]WIN35,428

binding

and

[3H]dopamine uptake at WT DAT (Tables 2 and 3). The binding affinities and
DUIPs of cocaine, mazindol, methylphenidate, WIN35,428, and 4-ARA-127 at
D79E DAT were identical (Table 2).

For 8-oxa-norcocaine and rimcazole,

however, the binding affinity at D79E DAT was 2 - 4 fold higher than DUIP.
Benztropine and GBR-12,909 were 3 fold less potent as inhibitors of
[3H]WIN35,428 binding than as inhibitors of [3H]dopamine uptake at D79E DAT
(Tables 2 and 3).
Seeing that the D79E mutation affected only the DUIP of benztropine, the
pharmacological profiles of structural analogs of this drug were further examined
at WT and D79E DAT. Except for 4',4"-difluoroBZT and GBR-12,909, the DUIPs
of all other benztropine analogs were diminished by the D79E mutation but to
different extents (Table 3). Intriguingly, the considerably different DUIPs of the
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Figure 9. Effect of DAT inhibitors on CHO cells stably expressing WT or D79E DAT
GBR-12,909 (squares), methylphenidate (diamonds) and benztropine (circles) inhibition
of [3H]-dopamine uptake (left graph) or [3H]-WIN 35,428 binding (right graph) under identical
conditions at CHO cells stably transfected with WT DAT (filled symbols) or D79E DAT (open
symbols). The data are representative of at least 3 independent experiments. Reprinted with
permission from ASPET from Ukairo et al., 2005.
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Figure 10. Effect of benztropine and BZT analogs on CHO cells stably expressing WT or
D79E DAT.
Benztropine (circles), 4'-chlorobenztropine (upright triangles) and 3β-4'-chlorobenztropine
(inverted triangles) inhibition of [3H]-dopamine uptake (left graph) or [3H]-WIN 35,428 binding
(right graph) under identical conditions at CHO cells stably transfected with WT (filled symbols) or
D79E DAT (open symbols). The data are representative of at least 3 independent experiments.
Reprinted with permission from ASPET from Ukairo et al., 2005.
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benztropine analogs (ranging from 15 – 964 nM) at the WT DAT were unified to
approximately 20 nM at D79E DAT (Fig. 10 and Table 3). Additional benztropine
analogs were investigated to assess the effects of adding larger groups to the
tropane and phenyl rings.

Replacement of the N-methyl group of 4',4"-

difluoroBZT with the charge-neutral N-formyl group (N-CHO-4,4’-diFBZT) caused
a profound reduction in DUIPs at both WT and D79E DAT (Table 3). Although
the D79E mutation increased the DUIP of this compound, the Ki for inhibiting
dopamine uptake diverged from the Ki of 20 nM at D79E DAT observed for other
benztropine analogs. The binding affinity of N-CHO-4,4’-diFBZT was increased
by 3 fold by the mutation. 4'-trifluoromethylBZT, a benztropine analog having a
larger aryl group on one of the phenyl rings, also diverged from the 20 nM DUIP
D79E

DAT

pattern.

The

D79E

mutation

increased

the

DUIP

of

4'-

trifluoromethylBZT by about 4 fold but had no effect on its binding affinity (Table
3). Interestingly, the 3β-4-chlorobenztropine compound (with its diphenyl ether
group in the β position) also yielded a DUIP of approximately 20 nM at D79E
DAT. The mutation caused a 37-fold increase in the DUIP of 3β-4chlorobenztropine in order to achieve the 20 nM DUIP.
For most of the benztropine analogs, the D79E mutation had no effect on
their binding affinities.

Increased binding affinities due to the mutation were

observed only for 3β-4-chloroBZT (3 fold) and N-formyl-difluoroBZT (5-fold)
(Table 3). The DUIP data of benztropine and its analogs suggested a connection
between modifications of the tropane ring C-3 position of cocaine and
modifications of the DAT D79 side chain.

65
Table 2. Dopamine uptake inhibition potencies and binding affinities of structurally
diverse DAT inhibitors at CHO cells stably expressing WT or D79E DAT.
Kd (WIN35,428 only) and Ki values were derived from experiments incubating the stablytransfected cells with nonradioactive ligands in the presence of [3H]dopamine or [3H]WIN35,428
at 22oC in KRH/AA buffer. Values are presented as Mean ± SEM for 3 - 6 independent
experiments. Of the 9 structurally diverse DAT blockers studied, only the DUIP of benztropine
was substantially altered by the D79E mutation. Reprinted with permission from ASPET from
Ukairo et al., 2005.

Ki (nM)
WT

D79E

74 ± 17
1630 ± 200
555 ± 29
9777 ± 1489
31 ± 3
152 ± 20
160 ± 37
15 ± 3
643 ± 43

71 ± 12
1540 ± 120
1126 ± 32b
8196 ± 340
47 ± 4
161 ± 9
19 ± 3b
40 ± 9
691 ± 76

20 ± 1c
3300 ± 40c
128 ± 5c
1564 ± 212c
13 ± 1c
57 ± 3c
127 ± 22
31 ± 5
180 ± 26c

68 ± 4b
1570 ± 210b
1066 ± 84b
5533 ± 653b,c
41 ± 3b
167 ± 2b
51 ± 5b,c
40 ± 9
226 ± 38c

3

[ H]- Dopamine uptake
WIN35,428a
ARA-127
Cocainea
Oxa-norcocaine
Mazindola
Methylphenidatea
Benztropine
GBR-12,909
Rimcazole
[3H]-WIN35,428 inhibition
WIN35,428a
ARA-127
Cocainea
Oxa-norcocaine
Mazindola
Methylphenidatea
Benztropine
GBR-12,909
Rimcazole

a

Wang et al. (2003) Mol. Pharmacol. 64: 430 - 439
P<0.05 versus WT DAT for that assay
c
P<0.05 for WIN inhibition vs. dopamine uptake at the same DAT construct
b
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Table 3. Dopamine uptake inhibition potencies and binding affinities of benztropine and
its analogs at CHO cells stably expressing WT or D79E DAT.
Ki values were derived from experiments incubating the stably-transfected cells with
nonradioactive inhibitors in the presence of [3H]dopamine or [3H]WIN35,428 at 22oC in KRH/AA
buffer. Values are presented as mean ± SEM for 3 - 6 independent experiments. Reprinted with
permission from ASPET from Ukairo et al., 2005.

Ki (nM)
WT DAT

D79E DAT

[ H] - Dopamine uptake
Benztropine
4-chloroBZT

160 ± 37
83 ± 6

19 ± 3a
19 ± 3a

3β-4-chloroBZT
4,4'-difluoroBZT
4-trifluoromethylBZT
N-CHO-4,4’-diFBZT
GBR-12,909

964 ± 161
22 ± 4
1282 ± 79
21760 ± 2857
15 ± 3

26 ± 4a
18 ± 3
330 ± 36a
1575 ± 452a
14 ± 3

[3H]–WIN35,428 inhibition
Benztropine

127 ± 22

51 ± 5a,b

4-chloroBZT
3β-4-chloroBZT
4,4'-difluoroBZT
4-trifluoromethylBZT
N-CHO-4,4’-diFBZT
GBR-12,909

45 ± 6b
680 ± 123
8 ± 1b
541 ± 71
12730 ± 1996
31 ± 5

44 ± 10b
120 ± 35a,b
9 ± 2b
359 ± 25
3840 ± 746a
40 ± 9

3

a

P<0.05 versus WT DAT for that assay
P<0.05 for WIN inhibition vs. dopamine uptake at the same DAT construct

b
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4. Effects of cell age, density and DAT cell surface expression on the
DUIPs of classical DAT inhibitors
Previous observations indicated that the DUIP of cocaine at WT DAT
varied with cell age (C.K. Surratt, unpublished data). The study was enlarged to
determine whether this phenomenon was unique to cocaine or could be
extended to other classical DAT inhibitors such as mazindol, methylphenidate,
and benztropine.

The influence of cell density (%confluence) and DAT cell

surface expression levels on inhibitor DUIP fluctuation was also investigated.
The WT DAT-CHO K1 stable cell line was used for the study. Cells in passages
9 - 20, 25 - 36, and 40 - 54 were described as “low”, “medium”, and “high”
passage cells, respectively. The DUIPs for these classical DAT blockers differed
between “low passage” (P9 - P20) and “high passage” (P40 - P54) WT DAT CHO
cells in a statistically significant fashion (Fig 11 and Table 4). The Ki value for
inhibition of [3H]dopamine uptake (for all the drugs tested) was about 2 fold less
at low passages when compared with high passage values. In contrast, assays
conducted in parallel indicated that apparent binding affinities (measured by
displacement of [3H]-WIN35,428) of these 4 inhibitors were not subject to cell
passage number.

WT DAT Bmax values for [3H]-WIN35,428 binding varied

significantly between the “low” and “high” passage cells; however, the Kd values
for all treatment groups remained unchanged (Table 4).
The DUIP of cocaine at WT DAT-CHO cells grown to different densities in
6-well plates was also investigated. Neither the DUIP nor the apparent binding
affinity of cocaine was influenced by the density (% confluence) of the cell
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monolayer (Table 5). The cells were grown to 20%, 100% and 150% confluence.
The monolayer is defined as “100% confluent” when all cells appeared to be in
contact with neighboring cells, so as not to leave open spaces on the culture
dish.
Manipulation of WT DAT expression level via transient transfection of
COS-7 cells with an amount of DAT plasmid cDNA 4-fold lower than optimal
resulted in a statistically significant fluctuation in the dopamine uptake inhibition
potency of cocaine (Table 6).
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Figure 11. Effect of methylphenidate on WT DAT-CHO cells of different passage numbers.
Methylphenidate inhibition of [3H]-dopamine uptake (left panel) or [3H]-WIN35,428 binding
(right panel) under identical conditions at WT DAT CHO cells of different passage number. The
data are representative of at least 3 independent experiments. Passages of 9 -20, 25 - 36 and 40
- 54 were classified as “low”, “medium” and “high”, respectively.
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Table 4. Effect of DAT blockers on WT DAT-CHO cells of different passage numbers.
Inhibition of [3H]-dopamine uptake or [3H]-WIN35,428 binding by classical DAT blockers
under identical conditions at WT DAT CHO cells of different passage number. Ki values were
derived from experiments incubating the stably-transfected cells with nonradioactive DAT
inhibitors in the presence of [3H]-dopamine or [3H]-WIN 35,428 at 22OC in KRH buffer. Passages
of 9 -20, 25 - 36 and 40 - 54 were classified as “low”, “medium” and “high”, respectively. (The
ranges for an individual drug were narrower, as testing with a given inhibitor was completed
before the next inhibitor was addressed). Mean ± SEM for at least 3 independent experiments.

Low

Cell Passage
Medium
High
Ki (nM)

[3H]-DA uptake inhibition
Cocaine
719 ± 94 1055 ± 52 1503 ± 127a
44 ± 4
352 ± 17
236 ± 40

74 ± 5
640 ± 22
395 ± 45

93 ± 17a
662 ± 45a
413 ± 27a

[3H]-WIN35,428 inhibition
Cocaine
179 ± 22
Mazindol
15 ± 2
Methylphenidate
74 ± 7
Benztropine
78 ± 6

197 ± 22
19 ± 2
72 ± 5
85 ± 9

251 ± 28
20 ± 2
85 ± 6
92 ± 10

17 ± 2
11 ± 2

18 ± 1
19 ± 3b

Mazindol
Methylphenidate
Benztropine

[3H]-WIN35,428 binding
Kd (nM)
Bmax (pmol/mg)

a

17 ± 1
9±2

P < 0.05 vs. low passages for the same drug in the uptake assay (one-way ANOVA, NewmanKeuls post hoc test)
b
P < 0.05 vs. low passages in the [3H]WIN35,428 saturation binding assay (one-way ANOVA,
Newman- Keuls post hoc test).
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Table 5. Effect of cell density on the DUIP and binding affinity of cocaine at WT DAT-CHO
cells.
Cocaine inhibition of [3H]-dopamine uptake or [3H]-WIN35,428 binding under identical
conditions at WT DAT CHO cells as a function of cell density (% confluence). Experiments were
carried out with intact cell monolayers at 20%, 100%, and 150% confluence. Ki values were
derived from experiments incubating the stably-transfected cells with cocaine in the presence of
[3H]-dopamine or [3H]-WIN35,428 at room temperature in KRH buffer. Data are mean ± SEM for 3
- 4 experiments.

Confluence (Cell Density)
20%
100%
150%
Ki (nM)
Cocaine
[ H]-DA uptake inhibition 505 ± 108 534 ± 109 540 ± 62
[3H]-WIN35,428 inhibition 260 ± 25 240 ± 12 201 ± 16
3

Kinetic analysis of [3H]dopamine uptake revealed a significant increase
(P<0.05, one-way ANOVA; n = 4) in Vmax of dopamine uptake in WT DAT-CHO
cells with increasing cell passage number (low<medium<high) (Fig 12 and Table
7).

This increase in Vmax was associated with an increase in WT-DAT cell

surface expression (Bmax) at higher passage numbers. The turnover number of
WT DAT (expressed as Vmax/Bmax), however, did not vary significantly between
the “low”, “medium” and “high” passage cells (Table 7). A statistical comparison
of the Vmax/Bmax values for the different groups was not possible as these are
ratios of mean values. “Low”, “medium” and “high” passage cells showed no
significant changes in Km values for [3H]dopamine uptake.
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Table 6. Effects of DAT cell surface expression on the DUIP of cocaine
Cocaine inhibition of [3H]-dopamine uptake by COS-7 cells transiently transfected with
various amounts of a plasmid cDNA encoding WT DAT. “PolyFect”-mediated transient
transfections were carried out using 375, 750 or 1500 ng WT DAT - pIRES plasmid per 35 mm
well containing a confluent monolayer of COS-7 cells. Cell monolayers were assayed for [3H]dopamine uptake and its inhibition by cocaine at room temperature in KRH buffer 48 hours after
transfection. Ki values are the Mean ± SEM for 3 experiments.

WT DAT – pIRES Plasmid
ng DNA / 35 mm well
375
750
1500
Ki (nM)
3

[ H]-DA uptake inhibition
Cocaine
[3H]-WIN35,428 binding
Kd (nM)
Bmax (pmol/mg)

a

228 ± 7

353 ± 20 558 ± 75a

12 ± 2
15 ± 2
0.8 ± 0.4 2.0 ± 0.5

14 ± 2
4.0 ± 0.2

P < 0.05 vs. dopamine uptake inhibition Ki values for assays employing 375 ng plasmid
transfections (one-way ANOVA, Newman-Keuls post hoc test)
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Figure 12. Dopamine uptake saturation kinetics of WT DAT CHO cells of different passage
numbers.
CHO cells stably transfected with WT DAT were incubated with increasing concentrations
of a fixed ratio of [3H]dopamine: nonradioactive dopamine (0.5 – 16 µM dopamine at 0.1 Ci/mmol)
as indicated in the method section. The data are representative of 4 independent experiments.
Passages of 9 -20, 25 - 36 and 40 - 54 were classified as “low”, “medium” and “high”,
respectively. Km and Vmax values were determined by fitting the rate versus concentration data.
The inset shows an Eadie- Hofstee plot of the data with lines drawn from the derived kinetic
constants. See Table 7 for a summary of the calculated data.
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Table 7. Kinetic and binding characteristics of rDAT wild-type in CHO cells of different
passage numbers.
Km and Vmax values were derived from uptake experiments incubating the WT DAT cells
with dopamine at 0.1 Ci/mmol for 5 min at 22oC. Nonlinear regression analysis was employed to
accurately determine Km and Vmax values. Bmax values were derived from [3H]WIN35,428
saturation binding experiments. Km, Vmax, and Bmax values are the mean ± SEM for at least three
independent experiments.

Cell Passage
Low
Medium
High
-1
a,b
Vmax(pmol/min.mg protein ) 681 ± 18 1136 ± 85
1645 ± 202a
Km (µM)
1.1 ± 0.2
1.4 ± 0.2
2.0 ± 0.4
Bmax (pmol/mg)
9±2
11 ± 2
19 ± 3c
Vmax/Bmax

a

76/min

103/min

87/min

P < 0.05 vs. low passages in the uptake assay (one-way ANOVA, Newman-Keuls post hoc test)
P < 0.05 vs. high passages in the uptake assay (one-way ANOVA, Newman-Keuls post hoc test)
c
P < 0.05 vs. low passages in the [3H]WIN35,428 saturation binding assay (one-way ANOVA,
Newman- Keuls post hoc test).
b
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B. Discussion
A TM 1 aspartic acid residue (Position 79 in the DAT) is conserved among the
NSS proteins that conduct the aromatic monoamine neurotransmitters dopamine,
norepinephrine, epinephrine and serotonin across the plasma membrane. This
negative charge on aspartic acid has been proposed to serve as the counter-ion
for the positively charged nitrogen atom present in all classical DAT inhibitors
including cocaine (Carroll et al., 1992). In the present study alanine, leucine,
asparagine or glutamate substitutions at this position were generated in order to
assess the importance of side chain length, hydrogen bonding potential and
negative charge for recognition of DAT inhibitors. Only the D79E DAT mutant
displayed detectable specific binding of [3H]-WIN35,428 (Fig. 1) or functional
uptake of [3H]dopamine (Fig. 2). Consequently, only WT DAT and D79E DAT
stably transfected cell lines were employed in the present study with a range of
DAT substrates as well as DAT blockers either structurally dissimilar to cocaine
or containing variations of the 3 primary components of the cocaine
pharmacophore, the positively charged tropane nitrogen atom, the tropane ring,
and the C-3 aromatic substituent.
Using various dopamine analogs, the possibility that D79 is involved in
recognition of some feature of the substrate catechol ring moiety was tested.
The dopamine uptake inhibition potencies for the tyramines and (-)-amphetamine
at WT versus D79E DAT indicated, however, that loss of one or both catechol
hydroxyl groups were essentially tolerated by D79E DAT. Binding affinities for
these three substrates, on the other hand, were reduced several fold by the
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mutation. The result suggests that different DAT conformations or populations
are responsible for DUIP and high affinity binding. Thus, one DAT conformation
or population is apparently more sensitive to alterations in the substrate catechol
moiety than is a second DAT conformation/population. An "aromatic pocket" role
for the DAT D79 residue is consistent with the fact that the aspartate is
conserved among the NSS proteins whose substrates bear an aromatic moiety.
A glycine residue is found in the analogous position for members of the same
transporter family that recognize nonaromatic substrates (eg. Glycine, GABA,
betaine) that nevertheless retain the protonated amino group (Wang et al., 2003).
As stated above, the aromatic moiety of dopamine would be the most logical
substrate functional group to show dependence on the D79 DAT residue.
To investigate the importance of the positive charge of cocaine to its
action at the DAT, we employed a compound for which the N-8 of the tropane
ring was replaced with a charge-neutral oxygen atom, a modification that has
previously been shown to spare dopamine uptake inhibition potency (DUIP) and
specific binding at WT DAT (Kozikowski et al., 1999). The Ki for inhibition of
dopamine uptake by 8-oxa-norcocaine at D79E DAT was similar to WT values;
binding affinity was, however, diminished by almost 4 fold (Table 1).

The

glutamate-for-aspartate switch is often thought of as a conservative mutation.
Recent findings indicate that although these two amino acids differ only by one
methylene group, they have different spatial preferences (Johnson and Peterson,
2001). Furthermore, aspartic acid has been shown to favor interactions between
the side chain carbonyl group and a backbone carbonyl group resulting in a ring-
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like structure which is not observed for glutamic acid (Deane et al., 1999).
Consequently, if D79 is actually situated in the binding pocket of the DAT, a
D79E mutation should introduce some steric hindrance to the ligand binding
cavity considering the different spatial preferences of the two amino acids. The
observation that the DUIP of this charge-neutral cocaine analog is unaltered by
an allegedly more crowded binding pocket is not in agreement with (but not
exclusive of) the postulate that a salt bridge between the D79 residue and the N8 atom is the principal, governing DAT - cocaine interaction.

The 8-oxa-

norcocaine compound paralleled cocaine in that Ki values suggest its affinity to
be several fold greater than its DUIP at WT DAT, and in that its affinity and DUIP
values were less than 2 fold apart at D79E DAT.
To verify the significance of the cocaine tropane ring with respect to the
D79 side chain, DAT inhibitors that possess a piperidine or piperazine in place of
the tropane ring were employed in binding and uptake inhibition assays (Table
2).

A number of piperidine-based cocaine analogs have been shown to be

effective in blocking binding of DAT ligands or dopamine uptake at the DAT
(Kozikowski et al., 1998; Tamiz et al., 2000), demonstrating that the tropane ring
of cocaine is not absolutely required for cocaine action at the transporter. The
compound employed in the present work, 4-ARA-127, is a WIN35,428 analog
that lacks the 6,7-bridgehead of the tropane ring and contains a p-chlorophenyl
instead of a p-fluorophenyl substituent on what would be C-3 of the tropane ring
(Fig. 3). The D79E mutation had little or no effect on the pharmacology of this
piperidine-based cocaine analog (Table 2). The D79E mutation also did not alter
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the pharmacological profile of the piperazine-based compounds, GBR-12,909
and rimcazole (Table 2). These data indicate that the role of the D79 residue
may not include recognition of the tropane ring (or piperidine/piperazine ring
replacement) of these DAT inhibitors.
It was predicted that the third position of the cocaine pharmacophore, an
aromatic group at the tropane C-3 position, would be the most sensitive to
alterations of the DAT D79 side chain.

For an inhibitor that directly blocks

dopamine binding at a DAT site in which the D79 residue is crucial, an aromatic
ring would be the more logical primary pharmacophore for this role. An aromatic
moiety is obligatory at the tropane C-3 position of cocaine for DAT inhibition, and
even for inhibitors missing the tropane structure an aromatic ring is necessary
(Carroll et al., 1992, Newman and Kulkarni, 2002). Based on this fact, the
contribution of the tropane C-3 substituent to DAT inhibition was investigated in
detail by testing benztropine, possessing one of the more pronounced structural
variations at this position, with the D79E mutant. Of 9 structurally diverse DAT
blockers initially studied, only the DUIP of benztropine was altered to a large
extent by the D79E mutation (Table 2).
It is possible that the D79E mutation influences recognition of the common
diphenylmethoxy pharmacophore given that benztropine and several of its
analogs yielded the same DUIP at D79E DAT despite often very different DUIPs
at WT DAT (Table 3). Unlike WT DAT, the D79E DAT protein was by and large
tolerant of diphenylmethoxy ring substituents, especially surprising considering
the marked reorientation of the diphenylmethoxy moiety in the 3β-4'-
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chlorobenztropine derivative. Optimal binding at the DAT is achieved when the
diphenyl ether of benztropine is in the axial or α-stereochemistry; both aryl rings
are required and cannot be held in a rigid cyclic structure (reviewed in Newman
and Kulkarni, 2002). The pharmacological profile of the different benztropine
analogs at D79E DAT suggests that the D79E substitution may have enhanced
DAT interaction with the diphenylmethoxy moiety possibly by providing a
"roomier" binding pocket for this pharmacophore that accommodates different
halogen substituents and ring orientations.

Both of the phenyl rings of

benztropine may simultaneously contribute to inhibition of D79E DAT, but likely
not when in the same plane. The phenyl rings of rimcazole are fused and thus
constrained in space by a bond that creates an intervening pyrrole ring (Fig. 8).
Comparing results (Table 2) for rimcazole to those for GBR-12,909, its closest
structural analog in this study, suggest that the phenyl rings must be able to
rotate freely for potent dopamine uptake inhibition at the DAT. Furthermore,
comparative molecular field analysis (CoMFA) of benztropines contends that the
relative orientation of the phenyl rings is important for DAT affinity (Kline et al.,
1997, Kulkarni et al., 2004).
There is accumulating evidence that benztropine employs a DAT binding site
distinguishable from other DAT blockers.

Newman and colleagues have

identified dissimilarities between benztropine and cocaine actions at the DAT via
distinctive structure-activity relationship profiles (Newman and Kulkarni, 2002).
Benztropine altered the accessibility of alkylation agents to wildtype DAT
cysteine residues in a pattern distinct from the pattern generated by cocaine,
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WIN35,428 and mazindol (Reith et al., 2001).

The latter study revealed a

primary alkylation pattern difference at C90, a DAT extracellular loop cysteine
residue that immediately follows TM 1. The notion that benztropine is recognized
by a DAT protein region encompassing the TM 1 D79 residue is supported by
other DAT structure-function findings. Chen and colleagues showed that the
binding affinities for benztropine and GBR12,909, but not those of cocaine or
WIN35,428, were Na+ dependent at W84L DAT, a mutation of a TM 1 residue
only 5 positions away from D79 (Chen et al., 2004).
In addition to different roles of the tropane ring nitrogen and the C-3 position
aromatic

functional

groups

between

cocaine-like

and

benztropine-like

compounds, the necessity and nature of the C-2 position substituent also differs
between these structural classes of DAT inhibitors (Newman and Kulkarni, 2002).
Cocaine and its analogues require a substituent in the C-2 position (e.g., a 2methyl ester for cocaine), a substituent not required for the benztropines to
exhibit high affinity for DAT.

Indeed, the only 2-methyl ester substituted

benztropine with affinity for the DAT presents this substituent in a
stereochemistry opposite to that of cocaine (Meltzer et al., 1994). These findings
have been confirmed and expanded (Zou et al., 2002; Zou et al., 2003), and
preliminary behavioral evaluation of the (+)-2-ester-substituted benztropines
suggests that the C-2 position substituent plays a role in the behavioral profile of
these compounds (Newman and Kulkarni, unpublished data).
From these SAR studies and the data herein, the influence of particular
functional groups within the C-3 pharmacophore appears to be weighted toward
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the aromatic ring system. In the benztropine class, the 4’,4”-difluorophenyl ether
provides optimal binding affinity at WT DAT. Molecular modeling of benztropine
and its most divergent analogs with respect to WT versus D79E DAT
pharmacology indicates that C-3 aromatic substituents that reduce DUIP at DAT
fall outside of the optimal binding pocket (Ukairo et al., 2005). The same is true
for the neutral tropane N-formyl group of AHN 2-032. Considering the significant
DUIP increases for these compounds with the D79E mutation, it may be that the
benztropine binding pocket is modified by the mutation to increase tolerance for
these C-3 or tropane nitrogen modifications.

With regard to the latter, it is

possible that the cocaine and benztropine recognition sites of DAT differ in that
D79 contributes to recognition of the C-3 pharmacophore of cocaine, but the
tropane nitrogen of benztropine. Nevertheless, it should be taken into account
that the D79E mutation-induced DUIP increase was only slightly more
pronounced for N-formylbenztropine compared to benztropine itself (Table 2).
The mechanism by which the D79E mutation influences the DAT binding
affinities of the various inhibitors tested remains uncertain. The D79E mutation
had little or no effect on the DUIPs of cocaine, WIN35,428, mazindol and
methylphenidate. Conversely, their binding affinities were reduced 3-4 fold by
this mutation (Wang et al., 2003).

The Ki value for displacement of

[3H]WIN35,428 binding at D79E DAT by these classical DAT inhibitors matched
their Ki values for inhibition of [3H]dopamine uptake. Binding Ki values for these
drugs diverged from their DUIP Ki values at WT DAT.

It appears that the

mutation eliminates the DAT site, conformation or population responsible for
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higher

affinity

binding

of

these

drugs,

while

sparing

the

site/conformation/population primarily responsible for inhibition of dopamine
uptake (Fig. 13) (Wang et al., 2003).

DAT Population 1

DAT Population 2

(Lower WIN Affinity)

(Higher WIN Affinity)

WT DAT and D79E DAT

DA
WIN

WT DAT only

DA

WIN

WIN

Figure 13. Model for dopamine uptake and WIN35, 428 binding at DAT
Two DAT populations (rectangular structures) are represented at the cell surface, within
the plasma membrane (parallel horizontal lines). The large majority of [3H]dopamine uptake is
proposed to be mediated by DAT population 1; population 2 is thus under-represented with
respect to total uptake of the dopamine radiotracer. Population 1 displays a lower affinity (~70
nM) for [3H]WIN 35,428 (WIN, inscribed in quasi-pentagonal structure) than does population 2
(~20 nM); Population 1 is thus underrepresented with respect to total binding of the WIN 35,428
radiotracer. Higher levels (e.g., >500 nM) of WIN 35,428 (or other DAT inhibitors employed in the
study) thoroughly eliminate dopamine uptake by both DAT populations, but the uptake inhibition
curves reflect actions principally at population 1 (the primary [3H]dopamine conduit). The D79E
mutation eliminates DAT population 2, eliminating the higher affinity binding of DAT inhibitors but
affording little or no effect on their dopamine uptake inhibition potencies. Reprinted from Wang,
Sonders, Ukairo et al., 2003.

The 8-oxa-norcocaine data are also in conformity with this hypothesis
(Table 2). In the case of benztropine and structurally analogous compounds,
binding affinities and DUIPs at WT DAT were lower than, or at best, equal to,
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those at D79E DAT (Table 3). Furthermore, binding affinities and DUIPs for
these compounds at D79E DAT were dissimilar.

For these drugs, the DAT

site/conformation/population responsible for higher affinity inhibitor binding is
likely to be different from that for cocaine, and may be affected differently by the
D79E substitution.
The idea of separate DAT populations, as opposed to simply multiple
binding sites or conformations, is supported by the observations that the DAT
and other monoamine transporter proteins form functional homooligomeric
complexes (Kilic and Rudnick, 2000; Hastrup et al., 2001; Schmid et al., 2001;
Hastrup et al., 2003; Kocabas et al., 2003) as well as complexes with membrane
and cytoskeletal proteins including Hic-5, PICK-1, α-synuclein and syntaxin 1A
(Torres et al., 2001; Carneiro et al., 2002; Wersinger and Sidhu, 2003; Lee et al.,
2004). In fact, the SNARE protein syntaxin 1A, inhibits substrate uptake via
direct interaction with GABA, glycine, serotonin and norepinephrine transporters,
all members of the NSS transporter family which includes the DAT (Beckman et
al., 1998; Geerlings et al., 2000; Haase et al., 2001; Sung et al., 2003). It has
been shown that the GABA transporter N-terminal aspartate residues directly
interacts with syntaxin 1A to modulate transporter function (Hansra et al., 2004).
It is conceivable, therefore, that the D79E mutation eliminates (or augments)
DAT populations consisting of complexes with syntaxins or other endogenous
factors (Ramsey and DeFelice, 2002). Some TM 1 mutations have been shown
to alter Na+ or Cl- binding, in turn altering inhibitor affinities (Mager et al., 1996;
Barker et al., 1999; Chen et al., 2004); possibly, the D79E mutation could
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manipulate availability of DAT sites, conformations or populations in this way. It
is intriguing to consider that structural modification of a DAT inhibitor may alter its
preference for a certain DAT population, in turn selectively affecting its behavioral
pharmacology.
The lack of correlation between DAT inhibitor DUIPs and apparent binding
affinities at the WT DAT is well-documented (Pristupa et al. 1994; Eshleman et
al. 1999) and has yet to be satisfactorily explained. In the course of this study
using mammalian cell lines stably-transfected with WT DAT cDNAs, it was
observed that the DUIP of a given inhibitor will fluctuate even though the
apparent binding affinity of the drug does not fluctuate. In order to investigate the
nature of this phenomenon, three possible influences on DAT function at the
level of the cultured cell were investigated: the age of the cell line (measured by
cell passage number), the density of the cell monolayer (i.e., percent
confluence), and the effect of varying DAT expression level by manipulation of
transfection conditions.

To ensure that comparisons between DUIP and

apparent binding affinity were legitimate for a given DAT inhibitor, [3H]-dopamine
uptake assays, binding assays involving the cocaine analog [3H]-WIN 35,428,
and versions of each assay that included nonradioactive competitors were
conducted under identical conditions.

As reported above, a conservative

glutamate-for-aspartate substitution in TM 1 of the rat DAT protein (D79E)
decreased apparent binding affinities of several classical DAT inhibitors by 3 - 8
fold, yet yielded little or no effect on the DUIPs of these blockers (Wang et al.,
2003). This finding implied that at least two discrete inhibitor-binding DAT sites,
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conformations or populations exist, and that in this CHO cell system at least, the
DAT site/conformation/population responsible for inhibitor high affinity binding is
less responsible for dopamine uptake. The present findings indicate that the
“age” of the WT DAT CHO cell line, as defined by cell passage number, appears
to be relevant to the DUIP for the classical DAT blockers cocaine, mazindol,
methylphenidate and benztropine. The DUIP of cocaine was also apparently
subject to DAT expression levels. These results can best be explained by a
model invoking two or more DAT populations, as opposed to two or more DAT
binding sites or conformations within the same DAT population.

The “cell

passage number” experiment indicated that DUIPs for all inhibitors tested
fluctuated suggesting that DAT function is regulated by an unidentified
intracellular agent, the actions of which are sensitive to cell state (e.g., cell age).
Reducing DAT expression while holding cell passage number constant also
caused cocaine DUIP to fluctuate.

Taken together, these results lead us to

postulate that inhibitor DUIP may be a property of the ratio of “naked” or
unmodified DAT molecules to “complexed” or posttranslationally-modified DAT
molecules.

DAT complexes may include homooligomers or heterooligomers

(with syntaxins or other endogenous proteins/factors capable of modulating DAT
function). For example, cellular aging may convert most of a “complexed” or
posttranslationally-modified population, which is less efficient in dopamine
transport but more efficient in binding the inhibitor, to the naked or unmodified
DAT population that is more efficient in dopamine transport but less efficient in
binding the inhibitor. This hypothesis is the subject of further investigation in our
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laboratory.

Given the fact that DAT is a phosphoprotein as well as a

glycoprotein, the use of inhibitors of DAT phosphorylation and glycosylation will
be employed to determine the involvement of these pathways in the observed
changes in inhibitor DUIP due to cell passages. In addition, the influence of DAT
oligomerization state on the observed phenomenon will also be investigated.
If certain DAT populations are more relevant to the mechanism(s) of
action of cocaine, amphetamines and other psychostimulants, characterization of
such populations may further development of novel therapeutics for these drugs
of abuse.
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IV.

CONCLUSIONS

Our results may be of significance to ongoing efforts in the development of
anti-cocaine medications. In addressing whether the D79 side chain contributes
to the DAT binding sites of other portions of the cocaine pharmacophore, only
inhibitors with variations of the tropane ring C-3 substituent, i.e., benztropine and
its analogs, displayed a considerably altered DUIP as a function of the D79E
mutation.

A single conservative amino acid replacement thus distinguished

structural requirements for benztropine function relative to those for all other
classical DAT inhibitors. Thus, it is possible to delineate the mechanism of action
of this DAT inhibitor, which has a low abuse liability, using DAT mutagenesis and
other structure-function studies. The development of drugs, including cocaine
and benztropine analogs, that inhibit DAT and yet display a distinct behavioral
profile from cocaine in animal models (Newman et al., 1994; Newman and
Kulkarni, 2002; Woolverton et al., 2002; Kozikowski et al., 2003) suggest that an
anti-cocaine medication is attainable.
The present results also indicate that while apparent binding affinities of
classic DAT blockers were unchanging at CHO cells stably transfected with the
wildtype rat DAT, the DUIPs for these inhibitors fluctuated as a function of cell
passage number. Manipulation of DAT levels in transiently-transfected COS-7
cells appeared to influence cocaine DUIP in these cells. These observations
suggest that an unidentified cellular agent modulates DAT inhibitor DUIP but not
binding affinity at the DAT protein.
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VII. ABSTRACT
A long-standing postulate holds that cocaine inhibits DAT-mediated
dopamine transport via competition with dopamine for formation of an ionic bond
with the DAT transmembrane 1 aspartic acid residue 79. A recent study from our
laboratory indicated that mutation of this aspartate to glutamate (D79E) had little
or no effect on dopamine affinity or dopamine uptake inhibition potencies for
WIN35,428 and cocaine, and decreased WIN35,428 affinity by only 3 fold (Wang
et al., 2003). The study cast doubt on the requirement of a dopamine-D79 ion
pair, but did not address whether the residue plays a role in recognizing the
cocaine pharmacophore.

In the present study, DAT inhibitors containing

variations of three primary components of this pharmacophore- the positively
charged tropane nitrogen atom, the seven-carbon tropane ring itself, and the
aromatic substituent at the tropane C-3 position- were assessed for binding
affinity and dopamine uptake inhibition at the same D79 DAT mutants. Only
inhibitors with modifications of the phenyl ring substituent of cocaine, i.e.
benztropine and its analogs, displayed considerably altered dopamine uptake
inhibition potency as a function of the D79E mutation. These observations may
suggest that the side chain of the D79 residue is important for the recognition of
the aromatic components of DAT ligands.
Furthermore, we investigated the influence of cell passage number, the
density of the cell monolayer and the effect of varying DAT expression levels by
manipulation of transfection conditions on DAT function. It was observed that the
DUIPs of cocaine, mazindol, methylphenidate, and benztropine fluctuated as a
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function of DAT-CHO cell passage number. The binding affinities of these DAT
inhibitors, however, remained static. Also, the DUIP of cocaine fluctuated as a
result of variations in DAT cell surface expression. It is therefore conceivable
that an unidentified cellular mediator modulates DAT inhibitor DUIP but not
binding affinity at the DAT protein.

